

CURRICULUM VITAE

BENEDETTO VITIELLO, M.D.



DEMOGRAPHIC AND PERSONAL INFORMATION

Date of birth: March 30, 1954

Place of birth: Mortara (Pavia), Italy

Current Appointments

Chief, Treatment and Preventive Interventions Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, National Institutes of Health

Professor of Psychiatry (adjunct), Johns Hopkins University, Baltimore, MD

Private practice in psychiatry and child psychiatry (part-time)

Personal Data

Office address: NIMH Room 7147
6001 Executive Boulevard
Bethesda, MD 20892-9633

Tel. 301/443-3357

Fax. 301/443-4045

E-mail: bvitiell@mail.nih.gov

Home address: 5801 Midhill Street
Bethesda, MD 20817

Tel. 301/263-0678

E-mail bvitiell@verizon.net

EDUCATION AND TRAINING

Medical Doctor/1978/University of Pavia Medical School, Collegio Ghislieri, Pavia, Italy

Residency in Pediatrics/1978-81/University of Genoa Medical School, Genoa, Italy

Residency in Psychiatry and Child Psychiatry/1984-89/ Medical College of Pennsylvania, Philadelphia, PA.

Senior Medical Staff Fellow/1989-91/National Institute of Mental Health, Bethesda, MD

PROFESSIONAL EXPERIENCE

1981-84/ Private practice in Pediatrics/ Milan, Italy.

1981-83/ Researcher in Clinical Pharmacology at Merrell-Dow-Lepetit Research Institute, Milan, Italy

1986-1989/Private practice in Psychiatry and Child Psychiatry (part time)/ Philadelphia, PA

1989-2003 and 2008-current/Private practice in Psychiatry and Child Psychiatry (part time)/ Bethesda, MD

1991-95/ Medical Officer (Psychiatrist)/Division of Neuroscience and Behavioral Sciences and Child and Adolescent Disorders Research Branch, National Institute of Mental Health, Rockville, MD

1995-97/ Medical Officer (Psychiatrist)/ Office on AIDS/ National Institute of Mental Health, Rockville, MD

1997- 2013/Chief of the Child & Adolescent Treatment & Preventive Intervention Research Branch/National Institute of Mental Health, Rockville, MD

2013-current/ Chief of the Treatment & Preventive Intervention Research Branch/National Institute of Mental Health, Rockville, MD

2005-07/Associate Professor of Psychiatry (adjunct), Johns Hopkins University, Baltimore, MD

2007-current/Professor of Psychiatry (adjunct), Johns Hopkins University, Baltimore, MD

RESEARCH ACTIVITIES

Citation Index: 13,742 citations (Web of Science, April 16, 2014)

Web of Science h index: 58

Scopus h index: 61

Peer-reviewed - Original Research Articles

1. Gargani GF, Vitiello B, et al.: Use of 2-thiol-propionamide-acetic acid in the treatment of cystic fibrosis. *Min Ped* 1980;32:1319-1322.
2. Vitiello B, Buniva G, et al.: Pharmacokinetics and metabolism of premarin, a new potential anxiolytic, in humans. *Int J Pharmacol Ther Toxicol* 1984;22:273-277.
3. Vitiello B, Ricciuti A, Behar D: PRN medications in child state hospital inpatients. *J Clin Psychiatry* 1987; 48:351-4. [Also published in JA Talbott (ed): *The Year Book of Psychiatry and Mental Health* 1989; pp. 128-129.]
4. Stoff D, Pollock L, Vitiello B, Behar D, Bridger WH: Reduction of ³H-imipramine binding sites on platelets of conduct disordered children. *Neuropsychopharmacol* 1987; 1:55-62.
5. Vitiello B, Behar D, Malone R, Ryan P, Delaney MA, Simpson GM: Pharmacokinetics of lithium carbonate in children. *J Clin Psychopharmacol* 1988; 8:355-539.
6. Vitiello B, Behar D, Spreat S: Obsessive-compulsive disorder in mentally retarded patients. *J Nerv Ment Dis* 1989; 177:232-236.
7. Vitiello B, Ricciuti A, Behar D, Stoff D, Denckla MB: Reliability of subtle (soft) neurological signs in children. *J Am Acad Child Adolesc Psychiatry* 1989; 28:749-753.
8. Stoff D, Friedman E, Pollock L, Vitiello B, Kendall PC, Bridger WH: Elevated MAO is related to impulsivity in boys with disruptive behavior disorders and in normal boys. *J Am Acad Child Adolesc Psychiatry* 1989; 28:754-760.
9. Gatti G, Barzaghi N, Attardo Parrinello G, Vitiello B, Perucca E: Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. *Int J Clin Pharm Res* 1989;9:385-389.
10. Vitiello B, de Leon J: Dismorphophobia misdiagnosed as obsessive-compulsive disorder. *Psychosomatics* 1990; 31:220-222.

11. Vitiello B, Malone R, Buschle P, Delaney MA, Behar D: Reliability of DSM-III diagnoses of hospitalized children. *Hospital & Community Psychiatry* 1990; 41:63-67.
12. Vitiello B, Stoff D, Atkins M, Mahoney A: Soft neurological signs and impulsivity in children. *J Dev Behav Pediatrics* 1990; 11:112-115.
13. Vitiello B, Behar D, Hunt J, Stoff D, Ricciuti A: Subtyping aggression in humans. *J Neuropsychiatry Clin Neurosciences* 1990;2:189-192.
14. Vitiello B, Behar D, Wolfson S, McLeer SV: Diagnosis of panic disorder in prepubertal children. *J Am Acad Child Adolesc Psychiatry* 1990; 29:782-784.
15. Singh H, Hunt J, Vitiello B, Simpson GM: Supersensitivity psychosis: a prospective study. *J Clin Psychiatry* 1990 ; 51: 319-321.
16. Stoff D, Ieni J, Friedman E, Bridger WH, Pollock L, Vitiello B: Platelet 3H-imipramine binding, serotonin uptake, and plasma alpha1 acid glycoprotein in disruptive behavior disorders. *Biol Psychiatry* 1991; 29:494-498.
17. Vitiello B, Shimon H, Behar D, Stoff D, Bridger WH, Friedman E: Platelet imipramine binding and serotonin uptake in obsessive-compulsive patients. *Acta Psychiat Scand* 1991; 84:29-32.
18. Sunderland T, Berrettini WH, Molchan SE, Lawlor BA, Martinez RA, Vitiello B, Tariot PN, Cohen RM: Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease. *Biol Psychiatry* 1991; 30:81-87.
19. Vitiello B, Hill J, Molchan S, Martinez, Martinson H, Sunderland T: Lack of seasonal variation in the births of patients with dementia of the Alzheimer's type. *Psychiatry Res* 1991; 39:21-24.
20. Vitiello B, Hill J, Elia J, Cunningham E, McLeer SV, Behar B: Placebo controlled study of p.r.n. medications in child psychiatric patients. *J Clin Psychiatry* 1991; 52:499-501.
21. Pappas BA, Sunderland T, Weingartner M, Vitiello B, Martinson H, Putnam K: Alzheimer's disease and feeling-of-knowing for knowledge and episodic memory. *J Gerontology* 1992; 47:P159-164.
22. Molchan SE, Mellow AM, Hill JL, Weingartner H, Martinez R, Vitiello B, Sunderland T: The effects of thyrotropin-releasing hormone and scopolamine in patients with Alzheimer's disease. *J Psychopharmacol* 1992; 6:489-500.
23. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T: Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. *Brain Res Rev* 1992;17:215-226.

24. Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, Mixon AJ, Weintraub BD: Attention deficit hyperactivity disorder in patients with generalized resistance to thyroid hormone. *N Engl J Med* 1993;328:997-1001.
25. Vitiello B, Veith R, Hill J, Molchan SE, Martinez RA, Radcliffe J, Sunderland T: Autonomic dysfunction in patients with dementia of the Alzheimer type. *Biol Psychiatry* 1993;34:428-433.
26. Molchan SE, Hill JL, Minichiello M, Vitiello B, Sunderland T: Scopolamine effects on the pressor response to thyrotropin-releasing hormone in humans. *Life Science* 1994;54:933-938.
27. Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells K: Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. *J Am Acad Child Adolesc Psychiatry* 1996;35:1304-1313.
28. Vitiello B, Martin A, Hill J, Mack C, Molchan S, Martinez R, Murphy DL, Sunderland T: Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. *Neuropsychopharmacology* 1997;16:15-24.
29. Heseltine PNR, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts W, Stover ES: Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. *Arch Neurol* 1998;55:41-51.
30. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB: Psychoactive medication prescribing practices for US children: Gaps between research and clinical practice. *J Am Acad Child Adolesc Psychiatry* 1999;38:557-565.
31. The MTA Cooperative Group: A 14-Month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (ADHD). *Arch Gen Psychiatry* 1999;56:1073-1086.
32. The MTA Cooperative Group: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder (ADHD). *Arch Gen Psychiatry* 1999;56:1088-1096.
33. Hoagwood K, Jensen PS, Feil M, Vitiello B, Bhatara V: Management of stimulants and other psychotropic medications in pediatric practice. *J Dev Behav Pediatr*. 2000;21:322-331.
34. Arnold LE, Aman MG, Martin A, Collier-Crespin, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle C, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F: Assessment in multisite randomized clinical trials of patients with autistic disorder: The Autism RUPP network. *J Autism Develop Disorders* 2000;30:99-111.

35. Sherbourne CD, Hays RD, Fleishman JA, Vitiello B, Magruder KM, Bing EG, McCaffrey D, Burnam A, Longshore D, Eggan F, Bozzette SA, Shapiro MF: Impact of psychiatric conditions on health-related quality of life in persons with HIV infections. *Am J Psychiatry* 2000;157:248-254.
36. March J, Swanson JM, Arnold LE, Hoza B, Conners CK, Hinshaw SP, Hechtman L, Kraemer HC, Greenhill LL, Abikoff HB, Elliott LG, Jensen PS, Newcorn JH, Vitiello B, Severe J, Wells KC, Pelham WE: Anxiety as a predictor of outcome variable in the Multimodal Treatment Study of Children with ADHD (MTA). *J Abnorm Child Psychol* 2000;28:527-541.
37. Wells KC, Epstein JN, Hinshaw SP, Conners CK, Klaric J, Abikoff HB, Abramowitz A, Arnold LE, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Pelham W, Piffner L, Severe J, Swanson JM, Vitiello B: Parenting and family stress treatment outcomes in attention deficit hyperactivity disorder (ADHD): An empirical analysis in the MTA study. *J Abnorm Child Psychol* 2000;28:543-553.
38. Hinshaw SP, Owens EB, Wells KC, Kraemer HC, Abikoff HB, Arnold LE, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hoza L, Jensen JS, March JS, Newcorn JH, Pelham WE, Swanson JM, Vitiello B, Wigal T: Family processes and treatment outcome in the MTA: Negative/ineffective parenting practices in relation to multimodal treatment. *J Abnorm Child Psychol* 2000;28:555-568.
39. Epstein JN, Conners CK, Erhardt D, Arnold LE, Hechtman L, Hinshaw SP, Hoza B, Newcorn JH, Swanson JM, Vitiello B: Familial aggregation of ADHD characteristics. *J Abnorm Child Psychol* 2000;28:585-594.
40. Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, Abikoff HB, Elliott G, Hechtman L, Hoza B, March JS, Newcorn JH, Severe JB, Vitiello B, Wells K, Wigal TJ: Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. *Dev Behav Pediatr* 2001;22:60-73.
41. Newcorn JH, Halperin JM, Jensen PS, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Epstein JN, Greenhill LL, Hechtman L, Hinshaw SP, Hoza B, Kraemer HC, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B: Symptom profiles with ADHD: effects of comorbidity and gender. *J Am Acad Child Adolesc Psychiatry* 2001; 40:137-146.
42. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B: ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. *J Am Acad Child Adolesc Psychiatry* 2001; 40:147-158.
43. Conners CK, Epstein JN, March JS, Angold A, Wells KC, Klaric J, Swanson JM, Arnold LE, Abikoff HB, Elliott GR, Greenhill LL, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, Newcorn JH, Pelham WE, Severe JB, Vitiello B, Wigal T:

Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. *J Am Acad Child Adolesc Psychiatry* 2001; 40:159-167.

44. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza, B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: success rate based on severity of ADHD and ODD symptoms at the end of treatment. *J Am Acad Child Adolesc Psychiatry* 2001; 40:168-179.
45. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T: Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. *J Am Acad Child Adolesc Psychiatry* 2001; 40:180-187.
46. Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein O, Elliott GR, Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell DP. Methylphenidate dosage for children with ADHD over time under controlled conditions: Lessons from the MTA. *J Am Acad Child Adolesc Psychiatry* 2001; 40(2):188-196.
47. Research Units on Pediatric Psychopharmacology Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. *N Engl J Med* 2001;344:1279-1285.
48. Bing E, Burnam MA, Longshorne D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro MF: Psychiatric disorders and drug use among Human Immunodeficiency Virus-infected adults in the United States. *Arch Gen Psychiatry* 2001;58:721-728.
49. Burnam MA, Bing E, Morton SC, Sherbourne C, Fleishman J, London AS, Vitiello B, Stein M, Bozzette SA, Shapiro MF: Use of mental health and substance abuse treatment services among adults with HIV in the United States. *Arch Gen Psychiatry* 2001;58:729-736.
50. Scahill L, McCracken J, McDougle C, Aman M, Arnold LE, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin M, McGough J, Posey DJ, Swiezy N, Volkmar F, Ritz L, Vitiello B: Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. *J Child Adolesc Psychopharmacol* 2001;11:377-388.

51. Greenhill LL, Vitiello B, Abikoff H, Levine J, March JS, Riddle MA, Capasso L, Cooper T, Davies M, Fisher P, Findling RL, Fried J, Labellarte M, McCracken J, McMahon DJ, Robinson J, Skrobala AM, Scahill L, Walkup J, Zito J: Improving the methods for evaluating the safety of psychotropic medications in children and adolescents. *Curr Ther Res* 2001;62:873-884.
52. Rieppi R, Greenhill LL, Ford RE, Chuang S, Wu M, Davies M, Abikoff H, Arnold LE, Conners CK, Elliott G, Hechtman L, Hinshaw S, Hoza B, Jensen P, Kraemer HC, Newcorn J, Pelham W, Severe J, Swanson J, Vitiello B, Wells K, Wigal T: Socioeconomic status as a moderator of ADHD treatment outcomes. *J Am Acad Child Adolesc Psychiatry* 2002; 41:269-277.
53. Hypericum Depression Trial Study Group: An Extract of *Hypericum perforatum* (St. John's Wort) in Major Depressive Disorder: a Randomized, Double-blind Trial with Placebo and Active Control. *JAMA* 2002;287:1807-1814.
54. Research Units on Pediatric Psychopharmacology Anxiety Study Group: The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. *J Am Acad Child Adolesc Psychiatry* 2002;41:1061-1069.
55. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. *N Engl J Med* 2002;347:314-321.
56. Abikoff HB, Jensen PS, Arnold LL, Hoza B, Hechtman L, Pollack S, Martin D, Alvir J, March JS, Hinshaw S, Vitiello B, Newcorn J, Greiner A, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Kraemer H, Pelham WE, Severe JB, Swanson JM, Wells K, Wigal T: Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. *J Abnorm Child Psychol* 2002;30:349-359.
57. Abikoff H, Arnold LE, Newcorn JH, Elliott GR, Hechtman L, Severe JB, Wigal T, Shapiro C, Cantwell DP, Conners CK, Greenhill LL, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Pelham WE, Swanson JM, Vitiello B, Wells KC: Emergency/ Adjunct services and attrition prevention for randomized clinical trials in children: the MTA manual-based solution. *J Am Acad Child Adolesc Psychiatry* 2002;41:498-504.
58. RUPP Anxiety Study Group: Treatment of pediatric anxiety disorders: an open-label extension of the RUPP anxiety study. *J Child Adolesc Psychopharmacol* 2002;12:175-188.
59. RUPP Anxiety Study Group: Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders. *J Am Acad Child Adolesc Psychiatry* 2003;42:13-21.
60. Vitiello B, Burnam A, Bing EG, Beckman R, Shapiro MF: Use of Psychotropic Medications Among HIV-Infected Patients in the United States. *Am J Psychiatry* 2003;160:547-554.

61. Treatment for Adolescents with Depression Study (TADS) Team: Treatment for Adolescents with Depression Study (TADS): rationale, design, and methods. *J Am Acad Child Adolesc Psychiatry* 2003;42:531-542.
62. Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliot G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Richters JE, Schiller EP, Severe JB, Swanson JM, Vereen D, Vitiello B, Wells KC, Wigal T: What treatment for whom for ADHD: Moderators of treatment response in the MTA. *J Consult Clin Psychol* 2003;71:540-552.
63. Arnold LE, Elliot M, Sachs L, Bird H, Kraemer HC, Wells KC, Abikoff HB, Comarda A, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hindshaw SP, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wigal T: Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. *J Consult Clin Psychol* 2003;71:713-27.
64. Arnold LE, Vitiello B, McDougale C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, Cronin P, Koenig K., Kohn AE, McMahan DJ., Tierney E: Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. *J Am Acad Child Adolesc Psychiatry* 2003;42:1443-1450.
65. Arnold LE, Chuang S, Davies M, Abikoff HB, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hinshaw SP, Hoza B, Jensen JS, Kraemer HC, Langworthy-Lam KS, March JS, Newcorn JH, Pelham WE, Severe SB, Swanson JM, Vitiello B, Wells KC, Wigal T: Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. *J Abnorm Child Psychol* 2004;32:39-51.
66. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougale CM, Tierney E, Chuang S, Vitiello B, and the Research Units on Pediatric Psychopharmacology Autism Network: Weight and leptin changes among risperidone-treated youths with autism: six-month prospective data. *Am J Psychiatry* 2004;161:1125-1127.
67. MTA Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. *Pediatrics* 2004;113:754-761.
68. MTA Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. *Pediatrics* 2004;113:762-769.
69. Bhatara V, Feil M, Hoagwood K, Vitiello B, Zima B: National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge. *J Atten Disord* 2004;7:217-226.

70. Treatment for Adolescents with Depression Study (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. *JAMA* 2004;292:807-820.
71. Hoza B, Gerdes AC, Mrug S, Hinshaw SP, Bukowski WM, Gold JA, Arnold LE, Abikoff HB, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Jensen PS, Kraemer HC, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T: Peer-outcomes at 14 months in the Multimodal Treatment Study of Children with ADHD (MTA). *J Clin Child Adolesc Psychology* 2005;34:74-86.
72. Greenhill LL, Vitiello B, Fisher P, Levine J, Davies M, Abikoff HB, Chuang S, Findling RL, March JS, Scahill L, Walkup J, Riddle MA: Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. *J Am Acad Child Adolesc Psychiatry* 2004;43:1488-1496.
73. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzales NM, Hollway J, Koenig K, McGough J, Ritz L, Vitiello B: Risperidone for the core symptom domains of autism: results from the RUPP Autism Network Study. *Am J Psychiatry* 2005;162:1142-1148.
74. Bann CM, Parker CB, Bradwejn J, Davidson JRT, Vitiello B, Gadde KM: Assessing Patient Beliefs in a Clinical Trial of Hypericum Perforatum in Major Depression. *Depression and Anxiety* 2004;20:114-122.
75. Treatment for Adolescents with Depression Study (TADS) Team: The Treatment for Adolescents with Depression Study (TADS): demographics and clinical characteristics. *J Am Acad Child Adolesc Psychiatry* 2005;44:28-40.
76. Vitiello B, Aman MG, Scahill L, McCracken JT, McDougle CJ, Tierney E, Davies M, Arnold LE: Research knowledge among parents of children participating in a randomized clinical trial. *J Am Acad Child Adolesc Psychiatry* 2005;44:145-149.
77. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. *Am J Psychiatry* 2005;162:1361-1369.
78. Abikoff HB, McGough J, Vitiello B, McCracken JT, Davies M, Walkup J, Riddle M, Melvin Oatis, M.D., Greenhill LL, Skrobala S, March J, Gammon P, Robinson J, Lazell R, McMahan D, Ritz L: Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders: The RUPP ADHD/Anxiety Study Group. *J Am Acad Child Adolesc Psychiatry*. 2005; 44:418-427.
79. Vitiello B, Shader RI, Corette B, Parker CB, Ritz L, Harlan W, Greenblatt DJ, Gadde KM, Krishnan KRR, Davidson JRT: Hyperforin Plasma Level as a Marker of

Treatment Adherence in the NIH Hypericum Depression Trial. *J Clin Psychopharmacol* 2005; 25:243-249.

80. Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliott G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K: Cost-effectiveness of ADHD treatments: findings from the Multimodal Treatment Study of Children with ADHD. *Am J Psychiatry* 2005;162:1628-1636.
81. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network : A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. *Arch Gen Psychiatry* 2005;62:1266-1274.
82. Kratochvil CJ, Simons A, Vitiello B, Walkup J, Emslie G, Rosenberg D, March JS : A multisite psychotherapy and medication trial for depressed adolescents: background and benefits. *Cognitive Behav Practice* 2005;12 :159-165.
83. Vitiello B, Davies M, Arnold LE, McDougle CJ, Aman M, McCracken JT, Scahill L, Tierney E, Posey DJ, Swiezy NB, Koenig K: Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone. *J Clin Psychopharmacol* 2005;565-569.
84. Arnold LE, Elliott M, Lindsay RL, Molina B, Cornelius MD, Vitiello B, Hechtman L, Elliott GR, Newcorn J, Epstein JN, Wigal T, Swanson JM, Wells K: Gestational and postnatal tobacco smoke exposure as predictor of ADHD, comorbid ODD/CD, and treatment response in the MTA. *Clin Neuroscience Res* 2005;5:295-306.
85. Hechtman L, Etcovitch J, Platt R, Arnold LE, Abikoff HB, Newcorn JH, Hoza B, Hinshaw SP, Kraemer HC, Wells K, Conners K, Elliott G, Greenhill LL, Jensen PS, March JS, Molina B, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wigal T: Does multimodal treatment of ADHD decrease other diagnoses? *Clin Neuroscience Res* 2005;5:273-282.
86. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL: Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. *J Child Adolesc Psychopharmacol* 2005;15:869-884.
87. Santosh PJ, Taylor E, Swanson J, Wigal T, Chuang S, Davies M, Greenhill L, Newcorn J, Arnold LE, Jensen P, Vitiello B, Elliott G, Hinshaw SP, Hechtman L, Abikoff H, Pelham WE, Hoza B, Molina B, Wells K, Epstein J, Posner M: Refining the diagnoses of inattention and overactivity syndromes: A reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. *Clin Neuroscience Res* 2005;5:307-314.
88. Epstein JN, Conners CK, Hervey AS., Tonev ST, Arnold LE, Abikoff HB, Elliott G, Greenhill LL, Hechtman L, Hoagwood K, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Wells K, Vitiello

- B, Wigal T: Assessing medication effects in the MTA study using neuropsychological outcomes. *J Child Psychol Psychiatry*. 2006;47:446-456.
89. Vitiello B, Zuvekas S, Norquist DG: National estimates of antidepressant medication use among U.S. children in 1997-2002. *J Am Acad Child Adolesc Psychiatry* 2006;45:271-279.
 90. Zuvekas SH, Vitiello B, Norquist NS: Recent trends in stimulant medication use among U.S. children. *Am J Psychiatry* 2006;163:579-585.
 91. Mazzone L, Vitiello B, Incorpora G, Mazzone D: Behavioral and temperamental characteristics of children and adolescents suffering from primary headache. *Cephalalgia* 2006;26:194-201.
 92. Vitiello B, Davis M, Greenhill LL, Pine D: Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamine. *J Child Adolesc Psychopharmacol* 2006;16:219-225.
 93. Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman GM, McCracken J, Tierney E, Arnold LE, Cronin P, Grados M, Ghuman J, Koenig K, Langworthy-Lam K, McGough J, Posey DJ, Ritz L, Swiezy NB, Vitiello B: The Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. *J Am Acad Child Adolesc Psychiatry* 2006;45:1114-1123.
 94. Lecavalier L, Aman MG, Scahill L, McDougle CJ, McCracken JT, Vitiello B, Tierney E, Arnold LE, Ghuman JK, Loftin RL, Cronin P, Koenig K, Posey DJ, Martin A, Hollway J, Lee LS, Kau ASM: The validity of the Autism Diagnostic Interview-Revised. *Am J Mental Retard* 2006;111:199-215.
 95. Williams SK, Scahill L, Vitiello B, Aman MG, Arnold LE, McDougle CJ, McCracken JT, Tierney E, Ritz L, Posey DJ, Swiezy NB, Hollway J, Cronin P, PhD, Ghuman J, Wheeler C, Cicchetti D, Sparrow S: Risperidone and Adaptive Behavior in Children with Autism. *J Am Acad Child Adolesc Psychiatry* 2006;45:431-439.
 96. Wells KC, Chi TC, Hinshaw SP, Epstein JN, Piffner L, Nebel-Schwalm M, Owens EB, Arnold LE, Abikoff H, Conners CK, Elliott G, Greenhill L, Hechtman L, Hoza B, Jensen P, March J, Newcorn J, Pelham W, Severe J, Swanson J, Vitiello B, Wigal T: Treatment Related Changes in Objectively Measured Parenting Behaviors in the Multimodal Treatment Study of Children with ADHD. *J Consult Clinical Psychol* 2006;74:649-657.
 97. Kollins SH, Greenhill LL, Swanson S, Wigal S, Abikoff H, McCracken JT, Riddle M, McGough JJ, Vitiello B, Wigal T, Skrobala AM, Posner K, Ghuman JK, Davies M, Cunningham C, Bauzo A: Rationale, Design, and Methods of the Preschool ADHD Treatment Study (PATS). *J Am Acad Child Adolesc Psychiatry* 2006;45:1275-1283.
 98. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman J, Cunningham C,

- Davies M, Chuang S, Cooper T. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry* 2006;45:1284-1293.
99. Wigal T, Greenhill LL, Chuang S, McGough JJ, Vitiello B, Skrobala AM, Swanson J, Wigal S, Abikoff H, Kollins SH, McCracken JT, Riddle M, Posner K, Ghuman JK, Davies M, Thorp B, Stehli A: Safety and tolerability of methylphenidate in preschool children with ADHD. *J Am Acad Child Adolesc Psychiatry* 2006;45:1294-1303.
 100. Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, Mccracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S : Stimulant-related reductions of growth rates in the PATS. *J Am Acad Child Adolesc Psychiatry* 2006;45:1304-1313.
 101. McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L, Abikoff H, Davies M, Chuang S, Wigal T, Wigal S, Posner K, Skrobala A, Kastelic E, Ghuman J, Cunningham C, Shigawa S, Moyzis R, Vitiello B : Pharmacogenetics of methylphenidate response in preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry* 2006;45:1314-1322.
 102. Goodkin K, Vitiello B, Lyman WD, Atkinson JH, Heseltine PNR, Molina R, Zheng W, Khamis I, Wilkie FL, Asthana D, Shapshak P: Cerebrospinal and peripheral human deficiency virus type 1 load in a multi-site, randomized, double blind, placebo-controlled trial of d-ala₁-peptide t-amide for associated cognitive-motor impairment. *J NeuroVirology* 2006;12:178-189.
 103. Scahill L, Aman MG, McDougale CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Poseu D, Young J, Shah B, Ghuman J, Titz L, Vitiello B: A prospective open trial of guanfacine in children with pervasive developmental disorders. *J Child Adolesc Psychopharmacol* 2006;16:589-98.
 104. Lindsay RL, Arnold LE, Aman M, Vitiello B, Posey DJ, McDougale CJ, Scahill L, Pachler M, McCracken JT, Tierney E, Bozzolo D: Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. *Journal of Intellectual Developmental Disability* 2006;31:204-209.
 105. Emslie GJ, Kratochvil CJ, Vitiello B, Silva SG, Mayes TL, McNulty S, Weller E, Waslick B, Casat C, Walkup J, Pathak S, Rohde P, March J: Treatment for Adolescents with Depression Study (TADS): safety results. *J Am Acad Child Adolesc Psychiatry* 2006;45:1440-1455.
 106. Curry JF, Rohde P, Simons A, Silva S, Vitiello B, Kratochvil CJ, , Reinecke MA, Feeny N, Wells KC, Pathak S, Weller E, Rosenberg D, Kennard BD, Robins M, Ginsburg GS, March JS: Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). *J Am Acad Child Adolesc Psychiatry* 2006;45:1427-1439.

107. Kratochvil CJ, Emslie GJ, Silva SG, McNulty S, Walkup J, Curry J, Reinecke MA, Vitiello B, Rohde P, Feeny NC, Casat C, Pathak S, Weller E, May D, Mayes TL, Robin M, March JS: Time to response for depressed adolescents receiving fluoxetine, cognitive-behavioral therapy, or combined treatment. *J Am Acad Child Adolesc Psychiatry* 2006;45:1412-1418
108. Kennard BD, Silva S, Vitiello B, Curry J, Kratochvil CJ, Simons A, Hughes JL, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie GJ, March J: Remission and residual symptoms after acute treatment of adolescents with major depressive disorder. *J Am Acad Child Adolesc Psychiatry* 2006;45:1404-1411.
109. Wagner A, Lecavalier L, Arnold LE, Aman MG, Scahill L, Stigler KA, Johnson C, McDougle CJ, Vitiello B: Developmental Disabilities Modification of Children's Global Assessment Scale (DD-CGAS). *Biol Psychiatry* 2007;19:629-635.
110. Vitiello B, Rohde P, Silva SG, Wells KC, Casat C, Waslick BD, Simons A, Reinecke MA, Weller EB, Kratochvil CJ, Walkup J, Pathak S, Robins M, March JS, and the TADS Team: Effects of treatment on level of functioning, global health, and quality of life in depressed adolescents. *J Am Acad Child Adolesc Psychiatry* 2006;45:1419-1426.
111. Posey DJ, Aman MG, McCracken JT, Scahill L, Tierney E, Arnold LE, Vitiello B, Chuang SZ, Davies M, Ramadan Y, Witwer A, Swiezy NB, Cronin P, Shah B, Carroll DH, Young C, Wheeler C, McDougle CJ: Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. *Biol Psychiatry* 2007;41:538-544.
112. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B: Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. *Biol Psychiatry* 2007;61:545-550.
113. Tierney E, Aman MG, Stout DJ, Pappas K, Arnold E, Vitiello B, Scahill L, McDougle CJ, McCracken JT, Wheeler C, Martin A, Posey DJ, Shah B. Parent satisfaction in a multi-site trial of risperidone in children with autism: a social validity study. *Psychopharmacology* 2007;191:149-157.
114. May DE, Kratochvil CJ, Puumla SE, Silva SG, Rezac AJ, Hallin MJ, Reinecke MA, Vitiello B, Weller EB, Pathak S, Simons AD, March JS: A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS). *J Am Acad Child Adolesc Psychiatry* 2007;46:573-581.
115. May DE, Hallin MJ, Kratochvil CJ, Puumala SE, Smith LS, Reinecke MA, Silva SE, Weller EB, Vitiello B, Breland-Noble A, March JS: Factors associated with recruitment and screening in the Treatment for Adolescents with Depression Study (TADS). *J Am Acad Child Adolesc Psychiatry* 2007;46:801-810.

116. Swanson J, Hinshaw SP, Arnold LE, Gibbons R, Marcus S, Hur K, Jensen PS, Vitiello B, Abikoff H, Greenhill LL, Hechtman L, Pelham W, Wells K, Conners CK, Elliott G, Epstein J, Hoagwood K, Hoza B, Molina B, Newcorn JH, Severe J, Odbert C, Wigal T, and the MTA Cooperative Group: Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. *J Am Acad Child Adolesc Psychiatry* 2007;46:1002-1013.
117. Molina BSG, Flory K, Hinshaw SP, Greiner AR, Arnold E, Swanson J, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliott GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Epstein J, Greenhill LL, Newcorn JH, Severe JB, Wigal T: Delinquent behavior and emerging substance use in the MTA at 36-months: Prevalence, course, and treatment effects. *J Am Acad Child Adolesc Psychiatry* 2007;46:1027-1039.
118. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein J, Pelham W, Abikoff HB, Newcorn J, Molina B, Hinshaw S, Wells K, Hoza B, Severe JB, Jensen PS, Gibbons R, Hur K, Stehli A, Davies M, March J, Caron M, Volkow ND, Posner MI, for the MTA Cooperative Group: Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. *J Am Acad Child Adolesc Psychiatry* 2007;46:1014-1026.
119. Jensen PS, Arnold LE, Swanson J, Vitiello B, Abikoff HB, Greenhill LL, Hechtman L, Hinshaw SP, Pelham WE, Wells KC, Conners CK, Elliott GR, Epstein J, Hoza B, Molina BSG, Newcorn JH, Severe JB, Wigal T, Gibbons RD, Hur K. Follow-up of the NIMH MTA study at 36 months after randomization. *J Am Acad Child Adolesc Psychiatry* 2007;46:988-1001.
120. McClellan J, Sikich L, Findling RL, Frazier JA, Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, Maloney AE, Ritz L, Anderson R, Hamer RM, Koch G, Lieberman JA: The Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design and Methods. *J Am Acad Child Adolesc Psychiatry* 2007;46:969-978.
121. Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotzky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, Ambler D, Hunt-Harrison T, Hamer RM, Noyes N, Lieberman JA, Sikich LM: Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. *J Am Acad Child Adolesc Psychiatry* 2007;46:979-988.
122. Vitiello B, Goodkin K, Ashtana D, Shapshak P, Atkinson JH, Heseltine PNR, Eaton E, Heaton R, Lyman WD: HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people. *AIDS* 2007;21:1415-1422.
123. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Parent training for children with pervasive developmental disorders: a multi-site feasibility trial. *Behav Interventions* 2007;22:179-199.

124. Johnson CR, Handen BL, Butter E, Wagner A, Mulick J, Sukhodolsky DG, Williams S, Swiezy NA, Arnold LE, Aman MG, Scahill L, Stigler KA, McDougle CJ, Vitiello B, Smith T: Development of a parent training program for children with pervasive developmental disorders. *Behav Interventions* 2007;22:201-221.
125. The TADS Team: The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. *Arch Gen Psychiatry* 2007;64:1132-1144.
126. Donfrancesco R, Calderoni D, Vitiello B: Open-label amantadine in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2007;17:657-663.
127. Posner K, Melvin GA, Murray DW, Gugga SS, Fisher P, Skrobala A, Cunningham C, Vitiello B, Abikoff HB, Ghuman JK, Kollins S, Wigal SB, Wigal T, McCracken JT, McGough JJ, Kastelic E, Boorady R, Davies M, Chuang SZ, Swanson JM, Riddle MA, Greenhill LL: Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). *J Child Adolesc Psychopharmacol* 2007;17:547-562.
128. Ghuman JK, Riddle MA, Vitiello B, Greenhill LL, Chuang SZ, Wigal SB, Kollins SH, Abikoff HB, McCracken JT, Murray DW, Evans L, Swanson JM, Wigal T, Posner K, Cunningham C, Davies M, Skrobala AM: Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). *J Child Adolesc Psychopharmacol* 2007;17:563-579.
129. Abikoff HB, Vitiello B, Riddle MA, Cunningham C, Greenhill LL, Swanson JM, Chuang SZ, Davies M, Kastelic E, Wigal SB, Evans L, Ghuman JK, Kollins SH, McCracken JT, McGough JJ, Murray DW, Posner K, Skrobala AM, Wigal T: Methylphenidate effects on functional outcomes in the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). *J Child Adolesc Psychopharmacol* 2007;17:581-592.
130. Vitiello B, Abikoff HB, Chuang SZ, Kollins SH, McCracken JT, Riddle MA, Swanson JM, Wigal T, McGough JJ, Ghuman JK, Wigal SB, Skrobala AM, Davies M, Posner K, Cunningham C, Greenhill LL: Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). *J Child Adolesc Psychopharmacol* 2007;17:593-603.
131. Murray DW, Kollins SH, Hardy KK, Abikoff HB, Swanson JM, Cunningham C, Vitiello B, Riddle MA, Davies M, Greenhill LL, McCracken JT, McGough JJ, Posner K, Skrobala AM, Wigal T, Wigal SB, Ghuman JK, Chuang SZ: Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). *J Child Adolesc Psychopharmacol* 2007;17:605-619.
132. Hardy KK, Kollins SH, Murray DW, Riddle MA, Greenhill L, Cunningham C, Abikoff HB, McCracken JT, Vitiello B, Davies M, McGough JJ, Posner K, Skrobala

- AM, Swanson JM, Wigal T, Wigal SB, Ghuman JK, Chuang SZ: Factor structure of parent- and teacher-rated attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). *J Child Adolesc Psychopharmacol* 2007;17:621-633.
133. Swanson JM, Moyzis RK, McGough JJ, McCracken JT, Riddle MA, Kollins SH, Greenhill LL, Abikoff HB, Wigal T, Wigal SB, Posner K, Skrobala AM, Davies M, Ghuman JK, Cunningham C, Vitiello B, Stehli A, Smalley SL: Effects of source of DNA on genotyping success rates and allele percentages in the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). *J Child Adolesc Psychopharmacol* 2007;17:635-645.
134. Vitiello B, Kratochvil CJ, Silva S, Curry J, Reinecke M, Pathak S, Waslick B, Hughes CW, Prentice ED, May DE, March JS: Research knowledge among the participants in the Treatment for Adolescents with Depression Study (TADS). *J Am Acad Child Adolesc Psychiatry* 2007;46:1642-1650.
135. Mazzone L, Ducci F, Scoto MC, Passaniti E, Genitori D'Arrigo V, Vitiello B: The role of anxiety symptoms in school performance in a community sample of children and adolescents. *BMC Public Health* 2007;7:347
136. Sukhodolsky DG, Scahill L, Gadow KD, Arnold LE, Aman MG, McDougle CJ, McCracken JT, Tierney E, Williams White S, Lecavalier L, Vitiello B: Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning, *J Abnorm Child Psychol* 2008;36:117-128.
137. Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, Kratochvil CJ: Antidepressant prescribing practices for the treatment of children and adolescents. *J Child Adolesc Psychopharmacol* 2008;18:70-80
138. Rohde P, Silva SG, Tonev ST, Kennard BD, Vitiello B, Kratochvil CJ, Reinecke MA, Curry JF, Simons AD, March JS: Achievement and maintenance of sustained response during TADS continuation and maintenance therapy. *Arch Gen Psychiatry* 2008; 65:447-455.
139. Domino M, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, Mario J, March JS: The cost-effectiveness of treatments for adolescent depression: results from the TADS randomized trial. *Am J Psychiatry* 2008; 165:588-596
140. Brent D, Emslie G, Clarke G, Wagner K, Asarnow J, Keller M, Vitiello B, Ritz L, Satish Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Porta G, Onorato M, Zelazny J: The Treatment of Adolescents with SSRI-Resistant Depression (TORDIA): a comparison of switch to venlafaxine or to another SSRI, with or without additional cognitive behavioral therapy. *JAMA* 2008;299:901-913.

141. Aman MG, Hollway JA, McDougle CJ, Scahill L, Tierney E, McCracken J, Arnold LE, Vitiello B, Ritz L, Gavaletz A, Cronin P, Swiezy NB, Wheeler C, Koenig K, Ghuman J, Posey DJ: Cognitive effects of risperidone in children with autism and irritable behavior. *J Child Adolesc Psychopharmacol* 2008;18:227-236.
142. Langberg JM, Epstein JN, Altaye M, Molina BSG, Arnold LE, Vitiello B: The transition to middle school is associated with changes in the developmental trajectory of ADHD symptomatology in young adolescents with ADHD. *J Clin Child Adolesc Psychol* 2008;37:651-63.
143. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Hunt-Harrison T, Jackson JA, De Jong S, Slifka K, Noyes N, Michael E, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Double-blind comparison of antipsychotics in early onset schizophrenia and schizoaffective disorder. *Am J Psychiatry* 2008; 165:1420-1431.
144. Jahromi LB, Kasari CL, McCracken JT, Lee LS, Aman MG, McDougle CJ, Scahill L, Tierney E, Arnold LE, Vitiello B, Ritz L, Witwer A, Kustan E, Ghuman J, Posey DJ: Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. *J Autism Dev Disord* 2009; 39:395-404.
145. Kennard B, Silva SG, Tonev S, Rohde P, Hughes JL, Vitiello B, Kratochvil CJ, Curry JF, Emslie GJ, Reinecke M, March J: Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. *J Am Acad Child Adolesc Psychiatry* 2009;48:186-195.
146. Nikolov RN, Bearss KE, Lettinga J, Erickson C, Rodowski M, Aman MG, McCracken JT, McDougle CJ, Tierney E, Vitiello B, Arnold LE, Shah B, Posey DJ, Ritz L, Scahill L: Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. *J Autism Dev Disorders* 2009; 39:405-413.
147. Kennard BD, Silva SG, Mayes TL, Rohde P, Hughes JL, Vitiello B, Kratochvil CK, Curry JF, Emslie GJ, Reinecke M, March J: Is acute treatment with pill placebo harmful to adolescents with MDD? Outcomes from the Treatment for Adolescents with Depression Study (TADS). *Am J Psychiatry* 2009;166:337-344.
148. Molina BSG, Hinshaw SP, Swanson JM, Arnold, LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L., Abikoff, H.B., Elliott GR, Greenhill LL, Newcorn, JH, Wells KC, Wigal TL, Gibbons RD, Hur K, Houck PR, and the MTA Cooperative Group: The MTA at 8 years: prospective follow-up of children treated for combined type ADHD in a multisite study. *J Am Acad Child Adolesc Psychiatry*. 2009; 48(5):484-500.
149. Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, Birmaher B, Ryan N, Kennard B, Mayes T, Debar L, McCracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D: Treatment of Selective Serotonin Reuptake Inhibitor-Resistant-Depression in

- Adolescents: predictors and moderators of treatment response. *J Am Acad Child Adolesc Psychiatry* 2009; 48:330-339.
150. Vitiello B, Silva S, Rohde P, Kratochvil C, Kennard B, Reinecke M, Mayes T, Posner K, May DE, March JS: Suicidal events in the Treatment for Adolescents with Depression Study (TADS). *J Clin Psychiatry* 2009;70:741-747.
 151. Scahill L, Aman MG, McDougle CJ, Arnold LE, McCracken JT, Handen B, Johnson C, Dziura J, Butter E, Sukhodolsky D, Swiezy N, Mulick J, Stigler K, Bearss K, Ritz L, Wagner A, Vitiello B: Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. *J Autism Dev Disord* 2009;39:720-729.
 152. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB: Predictors of spontaneous and systematically assessed suicidal adverse events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study. *Am J Psychiatry* 2009; 166:418-426.
 153. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke RA, March JS: The relative cost-effectiveness of Treatments for Adolescent Depression: 36-week Results from the TADS Randomized Trial. *J Am Acad Child Adolesc Psychiatry* 2009;48:711-720.
 154. Scahill L, Aman MG, McDougle CJ, Arnold LE, McCracken JT, Handen B, Johnson C, Dziura J, Butter E, Sulhodolsky D, Swiezy N, Mulick J, Stigler K, Bearss K, Ritz L, Wagner A, Vitiello B: Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. *J Autism Dev Disord* 2009; 39:720-729.
 155. Spirito A, Abebe KZ, Iyengar S, Brent D, Vitiello B, Clarke G, Wagner KD, Asarnow J, Emslie G, Keller M. Sources of site differences in the efficacy of a multi-site clinical trial: the Treatment of SSRI Resistant Depression in Adolescents. *J Consult Clinical Psychology*. 2009; 77:439-450.
 156. TADS Team: The Treatment for Adolescents with Depression Study (TADS): Outcomes Over One Year of Naturalistic Follow-up. *Am J Psychiatry* 2009; 166:1141-1149.
 157. Vitiello B, Brent D, Greenhill LL, Emslie G, Wells K, Walkup JT, Stanley B, Bukstein O, Kennard BD, Compton S, Coffey B, Cwik MF, Posner K, Wagner A, March JS, Riddle M, Goldstein T, Curry J, Capasso L, Mayes T, Shen S, Gugga SS, Turner JB, Barnett S, Zelazny J: Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters Study (TASA). *J Am Acad Child Adolesc Psychiatry* 2009;48:997-1004.

158. Stanley B, Brown G, Brent D, Wells K, Poling K, Curry J, Kennard BD, Wagner A, Cwik M, Klomek AB, Goldstein T, Vitiello B, Barnett S, Daniel S, Hughes J: Cognitive-Behavioral Therapy for Suicide Prevention (CBT-SP): Treatment Model, Feasibility, and Acceptability. *J Am Acad Child Adolesc Psychiatry* 2009;48:1005-1013.
159. Brent D, Greenhill LL, Compton S, Emslie G, Wells K, Walkup J, Vitiello B, Bukstein O, Stanley B, Posner K, Kennard BD, Cwik M, Wagner A, Coffey B, March J, Riddle M, Goldstein T, Curry J, Barnett S, Capasso L, Zelazny J, Hughes J, Shen S, Gugga S, Turner JB: The Treatment of Adolescent Suicide Attempters Study (TASA): Predictors of Suicidal Events in an Open Treatment Trial. *J Am Acad Child Adolesc Psychiatry* 2009;48:987-996.
160. Goldstein BI, Shamseddeen W, Spirito A, Emslie G, Clarke G, Wagner KD, Asarnow JR, Vitiello B, Ryan N, Birmaher B, Mayes T, Onorato M, Zelazny J, Brent DA: Substance Use and the Treatment of Resistant Depression in Adolescents. *J Am Acad Child Adolesc Psychiatry* 2009;48:1182-1192.
161. Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Karen Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Yaser Ramadan Y, Stacie L, Pozdol SL, Roumen Nikolov R, Lecavalier L, Arlene E. Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Kristy L. Hall, Dziura J, Louise Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A: Medication and parent training in children with pervasive developmental disorders and serious behavior problems. *J Am Acad Child Adolesc Psychiatry* 2009; 48:1143-1154.
162. Kratochvil CJ, May DE, Silva SG, Madaan V, Puumala SE, Curry JF, Walkup J, Kepley H, Vitiello B, March JS: Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the treatment for adolescents with depression study. *J Child Adolesc Psychopharmacol* 2009; 19:519-527.
163. Ruta L, Mugno D, D'Arrigo VG, Vitiello B, Mazzone L: Obsessive-compulsive traits in children and adolescents with Asperger syndrome. *Eur Child Adolesc Psychiatry* 2010; 19:17-24.
164. McCracken JT, Aman MG, McDougle CJ, Tierney E, Shiraga S, Whelan F, Arnold LE, Posey D, Ritz L, Vitiello B, Scahill L: Possible Influence of Variant of the P-Glycoprotein Gene (MDR1/ABCB1) on Clinical Response to Guanfacine in Children with Pervasive Developmental Disorders and Hyperactivity. *J Child Adolesc Psychopharmacol*. 2010; 20:1-5.
165. Domino ME, Burns BJ, Mario J, Reinecke MA, Vitiello B, Weller EB, Kratochvil CJ, May DE, Feeny NC, Robins M, Hallin MJ, Silva SG, March JS: Service use and costs of care for depressed adolescents: who uses and who pays? *J Clin Child Adolesc Psychol*. 2009;38:826-836.

- 166.Langberg JM, Arnold LE, Flowers AM, Epstein JN, Altaye M., Hinshaw SP, Swanson JM, Kotkin R, Simpson S, Molina BSG, Jensen PS, Abikoff H, Pelham WE, Vitiello B, Wells KC, Hechtman L: Parent-reported homework problems in the MTA study: Evidence for sustained improvement with behavioral treatment. *J Clin Child Adolesc Psychology* 2010;39(2):220-33.
- 167.Brent D, Melhem N, Ferrell R, Emslie G, Wagner KD, Ryan N, Vitiello B, Birmaher B, Mayes T, Zelazny J, Onorato M, Devlin B, Clarke G, Debar L, Keller M: Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. *Am J Psychiatry* 2010;167:190-197.
- 168.Denchev P, Kaltman J, Schoenbaum M, Vitiello B: A modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. *Circulation* 2010;121:1329-1337.
- 169.Hooper SR, Giuliano AJ, Youngstrom EA, Breiger D, Sikich L, Frazier JA, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA. Neurocognition in early-onset schizophrenia and schizoaffective disorders. *J Am Acad Child Adolesc Psychiatry* 2010;49:52-60.
- 170.Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. *J Am Acad Child Adolesc Psychiatry*. 2010;49(6):583-594.
- 171.Arnold L, Farmer C, Kraemer H, Davies M, Witwer A, Chuang S, DiSilvestro R, McDougale C, McCracken J, Vitiello B, Aman M, Scahill L, Posey D, Swiezy N: Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. *J Child Adolesc Psychopharmacol* 2010;20:83-93.
- 172.Emslie G, Mayes T, Porta G, Vitiello B, Clarke G, Wagner KD, Asarnow JR, Spirito A, Birmaher B, Ryan N, Kennard B, DeBar L, McCracken JT, Strober M, Onorato M, Zelazny J, Keller M, Iyengar S, Brent DA: Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. *Am J Psychiatry* 2010;167(7):782-91.
- 173.Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Birmaher B, Ryan N, Kennard B, Mayes T, DeBar L, Lynch F, Dickerson J, Strober M, Suddath R, McCracken JT, Spirito A, Onorato M, Zelazny J, Porta G, Iyengar S, Brent D: Long-term outcome of adolescent depression initially resistant to SSRI treatment. *J Clin Psychiatry* 2011; 71:388-396.
- 174.Sakolsky DJ, Perel JM, Emslie GJ, Clarke GN, Wagner KD, Vitiello B, Keller MB, Birmaher B, Asarnow JR, Ryan ND, McCracken JT, Strober MJ, Iyengar S, Porta G, Brent DA. Antidepressant exposure as a predictor of clinical outcomes in the

- Treatment of Resistant Depression in Adolescents (TORDIA) study. *J Clin Psychopharmacol* 2011;31(1):92-97.
175. Shamseddeen W, Asarnow JR, Clarke G, Vitiello B, Wagner KD, Birmaher B, Keller MB, Emslie G, Iyengar S, Ryan ND, McCracken JT, Porta G, Mayes T, Brent DA. Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). *J Am Acad Child Adolesc Psychiatry*. 2011 Mar;50(3):293-301.
 176. Lynch FL, Dickerson JF, Clarke G, Vitiello B, Porta G, Wagner KD, Emslie G, Asarnow JR Jr, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes T, Debar L, McCracken JT, Strober M, Suddath RL, Spirito A, Onorato M, Zelazny J, Iyengar S, Brent D. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: Treatment of SSRI-Resistant Depression in Adolescents trial findings. *Arch Gen Psychiatry*. 2011; 68(3):253-262.
 177. Asarnow JR, Porta G, Spirito A, Emslie G, Clarke G, Wagner KB, Vitiello B, Keller M, Birmaher B, McCracken J, Mayes T, Berk M, Brent DA. Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. *J Am Acad Child Adolesc Psychiatry* 2011;50(8):722-781.
 178. Lasky T, Krieger A, Elixhauser A, Vitiello B. Children's hospitalizations with a mood disorder diagnosis in general hospitals in the United States, 2000-2006. *Child Adolesc Psychiatry Mental Health* 2011; 5:27.
 179. Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W, McCracken JT, McDougle CJ, Vitiello B, Tierney E, Aman MG, Arnold LE, Katsovich L, Hoekstra PJ, Volkmar F, Bothwell AL, Kawikova I. Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. *J Child Adolesc Psychopharmacol*. 2011;21(6):555-564.
 180. Mattison DR, Plant TM, Lin HM, Chen HC, Chen JJ, Twaddle NC, Doerge D, Slikker W, Patton RE, Hotchkiss CE, Callicott RJ, Schrader SM, Turner TW, Kesner JS, Vitiello B, Dayton M, Petibone DM, Morris SM. Pubertal delay in male non-human primates (*Macaca mulatta*) treated with methylphenidate. *PNAS* 2011;108(39):16301-16306.
 181. Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, Molina BSG, Wells K, Wigal T, Jensen PS, Greenhill LL, Kaltman JR, Severe JB, Odbert C, Hur K, Gibbons R: Blood pressure and heart rate in the Multimodal Treatment of

- Attention Deficit/Hyperactivity Disorder Study over 10 years. *Am J Psychiatry*. 2012;169:167-177.
182. Zuvekas SH, Vitiello B: Stimulant medication use among U.S. children: a twelve-year perspective. *Am J Psychiatry*. 2012;169:160-166.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548321/>
183. Scahill L, McDougle CJ, Aman MG, Johnson C, Handen B, Bearss K, Dziura J, Butter E, Swiezy NB, Arnold LE, Stigler KA, Sukhodolsky DG, Lecavalier L, Pozdol SL, Nikolov R, Hollway JA, Korzekwa P, Gavaletz A, Kohn AE, Koenig K, Grinnon S, Mulick JA, Yu S, Vitiello B. Effects of risperidone and parent training on adaptive functioning in children with a pervasive developmental disorders and serious behavioral problems. *J Am Acad Child Adolesc Psychiatry* 2012; 51:136-146.
184. Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, Axelson DA, Bolhofner K, Robb A, Wolf DV, Riddle MA, Birmaher B, Nusrat N, Ryan ND, Vitiello B, Tillman R, Lavori P. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. *Arch Gen Psychiatry*. 2012;51(9):867-878.
185. Maalouf FT, Porta G, Vitiello B, Emslie G, Mayes T, Clarke G, Wagner KD, Asarnow JR, Spirito A, Keller M, Birmaher B, Ryan N, Shamseddeen W, Iyengar S, Brent D. Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study. *J Affect Disord*. 2012; 138(1-2):86-95.
186. Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA, Hooper SR. Neurocognitive outcomes in the treatment of early-onset schizophrenia spectrum disorders study. *J Am Acad Child Adolesc Psychiatry*. 2012;51(5):496-505.
187. Schoenbaum M, Denchev P, Vitiello B, Kaltman JR. Economic evaluation of strategies to reduce sudden cardiac death in young athletes. *Pediatrics* 2012; 130:1-10.
188. Vitiello B, Riddle MA, Yenokyan G, Axelson DA, Wagner KD, Joshi P, Walkup JT, Luby J, Birmaher B, Ryan ND, Emslie G, Robb A, Tillman R. Moderators and predictors of treatment outcome in child bipolar disorder. *J Am Acad Child Adolesc Psychiatry*. 2012;51(9):867-878.
189. Scahill L, Hallett V, Aman MG, McDougle CJ, Eugene Arnold L, McCracken JT, Tierney E, Deng Y, Dziura J, Vitiello B. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials. *J Autism Dev Disord* 2013 Mar;43(3):739-46. doi: 10.1007/s10803-012-1689-3.

190. Merikangas KR, He J, Rapoport J, Vitiello B, Olfson M. Medication use in US youth with mental disorders. *JAMA Pediatr.* 2013 Feb 1;167(2):141-8. doi:10.1001/jamapediatrics.2013.431. PMID: 23403911
191. Riddle MA, Yershova K, Lazzaretto D, Paykina N, Yenokyan G, Greenhill L, Abikoff H, Vitiello B, Wigal T, McCracken JT, Kollins SH, Murray DW, Wigal S, Kastelic E, McGough JJ, dosReis S, Bauz6-Rosario A, Stehli A, Posner K, and the PATS Study Group: The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-Year Follow-up. *J Am Acad Child Adolesc Psychiatry* 2013; 52(3):264-278.
192. Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S; MTA Cooperative Group. Adolescent substance use in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. *J Am Acad Child Adolesc Psychiatry.* 2013;52(3):250-63. doi: 10.1016/j.jaac.2012.12.014.
193. Hallett V, Lecavalier L, Sukhodolsky DG, Cipriano N, Aman MG, McCracken JT, McDougle CJ, Tierney E, King BH, Hollander E, Sikich L, Bregman J, Anagnostou E, Donnelly C, Katsovich L, Dukes K, Vitiello B, Gadow K, Scahill L. Exploring the Manifestations of Anxiety in Children with Autism Spectrum Disorders. *J Autism Dev Disord.* 2013; doi: 10.1007/s10803-013-1775-1 [published online Feb. 2013].
194. Nurmi EL, Spilman SL, Whelan F, Scahill LL, Aman MG, McDougle CJ, Arnold LE, Handen B, Johnson C, Sukhodolsky DG, Posey DJ, Lecavalier L, Stigler KA, Ritz L, Tierney E, Vitiello B, McCracken JT, and the Research Units on Pediatric Psychopharmacology Autism Network. Moderation of Antipsychotic-Induced Weight Gain by Energy Balance Gene Variants in the RUPP Autism Network Risperidone Studies. *Translational Psychiatry.* 2013 Jun 25;3:e274. doi: 10.1038/tp.2013.26.
195. McCracken JT, Badashova KK, Posey DJ, Aman MG, Scahill LL, Tierney E, Arnold LE, Vitiello B, Whelan F, Chuang SZ, Davies M, Shah BG, McDougle CJ, Nurmi EL. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. *The Pharmacogenomics Journal* (in press), 2013.
196. Handen BL, Johnson CR, Butter EM, Lecavalier L, Scahill , Aman MG, McDougle CJ, Arnold LE, Swiezy NB, Sukhodolsky DG, Mulick JA, White SW, Bearss K, Hollway JA, Stigler KA, Dziura J, Yu S, Sacco K, Vitiello B. Use of a Direct Observational Measure in a trial of risperidone and parent training in children with pervasive developmental disorders. *J Dev Physical Disabilities* 2013; 25:355–371. DOI 10.1007/s10882-012-9316-y
197. Carroll D, Hallett, V, McDougle CJ, Aman MG, McCracken JT, Tierney E, Arnold LE, Sukhodolsky DG, Lecavalier L, Handen B, Swiezy N, Johnson

C, Bearss K, Vitiello B, Scahill L. Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems. *Child Adolesc Psychiatr Clin N Am* 2014;23(1):57-72.

198. Scahill L, Dimitropoulos A, McDougale CJ, Aman MG, Feurer ID, McCracken JT, Tierney E, Pu J, White S, Lecavalier L, Hallett V, Bearss K, King B, Arnold LE, Vitiello B. Children's Yale-Brown Obsessive Compulsive Scale in Autism Spectrum Disorder: Component Structure and Correlates of Symptom Checklist. *J Am Acad Child Adolesc Psychiatry*. 2014;53(1):97-107. doi: 10.1016/j.jaac.2013.09.018.

Extramural Funding

I have worked at NIH, intramurally (1989-91) and extramurally (1991-present). So, my research activities have been funded by the National Institute of Mental Health as part of my employment.

Research Program Building/Leadership

1994-current: I built research program in pediatric psychopharmacology and clinical trials at the National Institute of Mental Health, as government program official. The following are some of the research initiatives and studies launched under my tenure: Research Units on Pediatric Psychopharmacology (RUPP) Network (1996-2007), NIH Hypericum perforatum Depression Study (1999-2002), Treatment for Adolescents with Depression Study (TADS, 1999-2007), Preschoolers with ADHD Treatment Study (PATS, 2001-2008), Treatment of Resistant Depression in Adolescents (TORDIA, 2000- 2007), Treatment of Early Onset Schizophrenia Study (TEOSS, 2001-2007), Child Anxiety Multimodal Study (CAMS, 2002-2008), Treatment of Early Onset Mania (TEAM, 2002-2009).

EDUCATIONAL ACTIVITIES

Educational publications

Peer-reviewed – Consensus statements, expert opinion

1. Vitiello B, Bhatara VS, Jensen PS: Current knowledge and unmet needs in pediatric psychopharmacology. *J Am Acad Child Adolesc Psychiatry* 1999;38:501-502.
2. Vitiello B, Jensen PS, Hoagwood K: Integrating science and ethics in child and adolescent psychiatry research. *Biol Psychiatry* 1999;46:1044-1049.
3. Vitiello B, I. Lederhendler: Research on Eating Disorders: Current Status, Future Prospects. *Biol Psychiatry* 2000;47:777-786.
4. Vitiello B: Psychopharmacology for young children: clinical needs and research opportunities. *Pediatrics* 2001;108:983-989.

5. Greenhill LL, Jensen PS, Abikoff H, Blumer JL, DeVeugh-Geiss J, Fisher C, Hoagwood K, Kratochvil CJ, Lahey BB, Laughren T, Leckman J, Petti TA, Pope K, Shaffer D, Vitiello B, Zeanah C: Developing strategies for psychopharmacological studies in preschool children. *J Am Acad Child Adolesc Psychiatry* 2003;42:406-414.
6. Vitiello B: Ethical considerations in psychopharmacological research involving children and adolescents. *Psychopharmacol* 2003;171:86-91.
7. Vitiello B, Riddle MA, Greenhill LL, March JS, Levine J, Schachar R, Abikoff H, Zito J, McCracken J, Walkup J, Findling RL, Robinson J, Cooper T, Davies M, Varipatis E, Labellarte M, Scahill L, Capasso L: How Can We Improve the Assessment of Safety in Child and Adolescent Psychopharmacology? *J Am Acad Child Adolesc Psychiatry* 2003; 42:634-641.
8. Greenhill LL, Vitiello B, Abikoff H, Levine J, March JS, Riddle MA, Capasso L, Cooper TB, Davies M, Fisher P, Findling RL, Fried J, Labellarte MJ, McCracken JT, McMahon D, Robinson J, Skrobala A, Scahill L, Varipatis E, Walkup JT, Zito JM: Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH Conference, September 25, 2000. *J Am Acad Child Adolesc Psychiatry* 2003; 42:651-655.
9. Hinshaw SP, Hoagwood K, Jensen PS, Kratochvil C, Bickman L, Clarke G, Abikoff HB, Atkins M, Vitiello B: AACAP 2001 Research Forum: Challenges and Recommendations Regarding Recruitment and Retention of Participants in Research Investigations. *J Am Acad Child Adolesc Psychiatry* 2004;43:1037-1045.
10. Vitiello B, Heiligenstein JJ, Riddle MA, Greenhill LL, Fegert JM: The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. *Biol Psychiatry* 2004;56:3-9.
11. March J, Kratochvil C, Clarke G, Beardslee W, Derivan A, Emslie G, Green EP, Heiligenstein J, Hinshaw S, Hoagwood K, Jensen P, Lavori P, Leonard H, McNulty J, Michaels MA, Mossholder A, Osher T, Petti T, Prentice E, Vitiello B, Wells K: AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. *J Am Acad Child Adolesc Psychiatry* 2004;43:1046-1056.
12. DeVeugh-Geiss J, March J, Andreason P, Clary C, Emslie G, Ford L, Greenhill L, Murphy D, Prentice E, Roberts R, Silva S, Swanson S, van Zwieten-Boot B, Vitiello B, Wagner KD, Shapiro M, Mangum B: A Workshop on Child and Adolescent Psychopharmacology in the New Millennium. *J Am Acad Child Adolesc Psychiatry* 2006;45:261-270.
13. Jensen PS, Youngstrom E, Steiner H, Findling RL, Meyer RE, Malone RP, Carlson GA, Coccaro EF, Aman MG, Blair J, Dougherty D, Ferris C, Flynn L, Green E, Hoagwood K, Hutchinson J, Laughren T, Leve LD, Novins DK, Vitiello B: Consensus Report: Impulsive Aggression as a Symptom across Diagnostic Categories in Child Psychiatry:

Implications for Medication Studies. *J Am Acad Child Adolesc Psychiatry* 2007;46):309-322.

14. Hughes CW, Emslie GJ, M. Lynn Crismon ML, Posner K, Birmaher B, Ryan N, Jensen P, Curry J, Vitiello B, Lopez M, Shon SP, Pliszka S, Trivedi MH : Update from Texas consensus conference panel on medication treatment of childhood major depressive disorder. *J Am Acad Child Adolesc Psychiatry* 2007; 46:667-686.
15. Kratochvil CJ, Vitiello B, Walkup J, Emslie G, Waslick BD, Weller EB, Burke WJ, March JS: SSRIs in Pediatric Depression: Is the Balance Between Benefits and Risks Favorable? *J Child Adolesc Psychopharmacol* 2006;16:11-24.
16. March JS, Silva SG, Vitiello B: The Treatment for Adolescents with Depression Study (TADS): Methods and message at twelve weeks. *J Am Acad Child Adolesc Psychiatry* 2006;45:1393-1403
17. Vitiello B: An update on publicly funded multisite trials in pediatric psychopharmacology. *Child Adolesc Psychiatr Clin N Am* 2006;15:1-12.
18. Vitiello B: Research in Child and Adolescent Psychopharmacology: Recent Accomplishments and New Challenges. *Psychopharmacol* 2007;191:5-13.
19. Vitiello B: Understanding the risk of using medications for attention-deficit/hyperactivity disorder with respect to physical growth and cardiovascular function. *Child Adolesc Psychiatric Clinic N Am* 2008;17:459-474.
20. Vitiello B: An international perspective on pediatric psychopharmacology. *Int Rev Psychiatry* 2008;20:121-126.
21. Vitiello B: Effectively obtaining informed consent for child and adolescent participation in mental health research. *Ethics & Behavior* 2008;18:182-198.
22. Vitiello B, Pearson JL: An adolescent at high risk for suicidal behavior. *Am J Psychiatry* 2008;165:323-328.
23. Vitiello B: Recent developments and strategies in pediatric pharmacology research in the U.S.A. *Child Adolesc Psychiatry Mental Health* 2008; 2:36.
24. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, Vitiello B, Jensen P, Steinhoff K, Lerner M, Greenhill L, Abikoff H, Wells K, Epstein J, Elliott G, Newcorn J, Hoza B, Wigal T; MTA Cooperative Group: Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. *J Atten Disord* 2008;12:4-14.
25. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, Vitiello B, Jensen P, Steinhoff K, Lerner M, Greenhill L, Abikoff H, Wells K, Epstein J, Elliott G, Newcorn J, Hoza B, Wigal T: Evidence, interpretation, and qualification from multiple

reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. *J Atten Disord* 2008;12:15-43.

26. Vitiello B: Combined cognitive-behavioural therapy and pharmacotherapy for adolescent depression: does it improve outcomes compared with monotherapy? *CNS Drugs* 2009;23:271-80.
27. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. *European Neuropsychopharmacology* 2009;19:629-635.
28. March JS, Vitiello B: Clinical Messages from the Treatment for Adolescents with Depression Study (TADS). *Am J Psychiatry* 2009; 166:1118-1123.
29. Wagner KD, Asarnow JR, Vitiello B, Clarke G, Keller M, Emslie G, Ryan N, Porta G, Iyengar S, Ritz L, Zelanzny J, Onorato M, Brent D. Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. *J Child Adolesc Psychopharmacol.* 2012;22:5-10.

Review Articles (peer-reviewed)

1. Vitiello B, Behar D: Mental retardation and psychiatric illness. *Hosp Community Psychiatry* 1992; 43:494-499.
2. Vitiello B: Treatment algorithms in child psychopharmacology research. *J Child Adolesc Psychopharmacol* 1997;7:3-8.
3. Vitiello B, Stoff DM: Subtypes of aggression and their relevance to child psychiatry. *J Am Acad Child Adolesc Psychiatry* 1997;36:307-315.
4. Vitiello B, Jensen PS: Medication development and testing in children and adolescents. *Arch Gen Psychiatry* 1997;54:871-876.
5. Vitiello B: Pediatric psychopharmacology and the interaction between drugs and the developing brain. *Can J Psychiatry* 1998;43:582-584.
6. Vitiello B: Hypericum perforatum extracts as potential antidepressants. *J Pharmacy Pharmacol* 1999;51:513-517.
7. McDougale C, Scahill L, Mc Cracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGough JJ, Cronin P, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B, Volkmar FR, Votolato NA, Walson P: Research Units on Pediatric Psychopharmacology (RUPP) autism network. *Child Adolesc Psychiatric Clinics North America* 2000;9:201-224.

8. Vitiello B: Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. *J Child Adolesc Psychopharmacology* 2001;11:25-34.
9. Greenhill LL, Vitiello B, Riddle MA, Fisher P, Shockey E, March JS, Levine J, Fried J, Abikoff H, Zito JM, McCracken JT, Findling RL, Robinson J, Cooper TB, Davies M, Varipatis E, Labellarte MJ, Scahill L, Walkup JT, Capasso L, Rosengarten J: Review of safety assessment methods used in pediatric psychopharmacology. *J Am Acad Child Adolesc Psychiatry* 2003; 42:627-633.
10. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, Vitiello B, Jensen P, Steinhoff K, Lerner M, Greenhill L, Abikoff H, Wells K, Epstein J, Elliott G, Newcorn J, Hoza B, Wigal T: Evidence, Interpretation, and Qualification From Multiple Reports of Long-Term Outcomes in the Multimodal Treatment Study of Children With ADHD (MTA): Part I: Executive Summary. *J Atten Disord* 2008;12:4-14.
11. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, Vitiello B, Jensen P, Steinhoff K, Lerner M, Greenhill L, Abikoff H, Wells K, Epstein J, Elliott G, Newcorn J, Hoza B, Wigal T: Evidence, Interpretation, and Qualification From Multiple Reports of Long-Term Outcomes in the Multimodal Treatment Study of Children With ADHD (MTA): Part II: Supporting Details. *J Atten Disord* 2008;12:15-43.
12. Vitiello B: Recent NIMH clinical trials and implications for practice. *J Am Acad Child Adolesc Psychiatry* 2008;47:1369-74.
13. Vitiello B: Prevention and Treatment of Child and Adolescent Depression: Challenges and Opportunities. *Epidemiol Psychiatr Sci* 2011;20:37-43.

Editorials

1. Vitiello B, Hoagwood K: Pediatric pharmacoepidemiology: Clinical applications and research priorities in children's mental health. *J Child Adolesc Psychopharmacol* 1997;7:287-290.
2. Vitiello B: Commentary to: Angold et al.: Stimulant treatment for children: a community perspective. *J Am Acad Child Adolesc Psychiatry* 2000;39:992-994.
3. Rumsey JM, Vitiello B, Cooper J, Hirtz D: Preface to the special issue: Treatments for People with Autism and other Pervasive Developmental Disorders: Research Perspectives. *J Autism Dev Dis* 2000;30:369-371.
4. March JS, Vitiello B: Advances in paediatric neuropsychopharmacology: an overview. *Int J Neuropsychopharmacol* 2001;4:141-147.

5. Vitiello B: Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. *Can Med Assoc J* 2001;165:1505-1506.
6. Vitiello B, Swedo S: Antidepressant medications in children and adolescents. *N Engl Med J* 2004;350:1489-1491.
7. Vitiello B: Pharmacoepidemiology and pediatric psychopharmacology research. *J Child Adolesc Psychopharmacol* 2005;15:10-11.
8. Kratochvil JC, Vitiello B, Brent D, Bostic JQ, Naylor NW: Selecting an antidepressant for the treatment of pediatric depression. *J Am Acad Child Adolesc Psychiatry* 2006;45:371-373.
9. Vitiello B: Selective serotonin reuptake inhibitors (SSRIs) in children and adolescents. *J Child Adolesc Psychopharmacol* 2006;16:7-9.
10. Vitiello B: Commentary to Reyes et al.: Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behavior disorders. *Evid Based Mental Health* 2006;9:105.
11. Wang PS, Sherrill J, Vitiello B: Unmet need for services and interventions among adolescents with mental disorders. *Am J Psychiatry* 2007;164:1-3.
12. Vitiello B, Wagner A: The rapidly expanding field of autism research. *Biol Psychiatry*, 2007;41:427-428.
13. Vitiello B, Sherrill J: School-based interventions for students with attention deficit hyperactivity disorder: research implications and prospects. *School Psychology Rev* 2007;36:287-290.
14. Fegert J, Vitiello B: Peer-reviewed, high quality, worldwide information on all topics relevant to child and adolescent mental health. *Child Adolesc Psychiatry Ment Health* 2007;1(1).
15. Vitiello B: Improving decision making in the treatment of ADHD. *Am J Psychiatry* 2008; 165:666-667.
16. Riddle MA, Walkup JT, Vitiello B: Introduction: issues and viewpoints in pediatric psychopharmacology. *Int Rev Psychiatry* 2008;20:119-120.
17. Fegert J, Vitiello B: Child and Adolescent Psychiatry and Mental Health: development of a new open-access journal. *Child Adolesc Psychiatry Ment Health* 2008; 2:22.

18. Vitiello B: Treatment of adolescent depression: what we have come to know. *Depress Anxiety* 2009; 29:393-395.
19. March JS, Vitiello B: Benefits exceed risks of newer antidepressant medications in youth-maybe. *Clin Pharmacol Ther* 2009; 86:355-357.
20. Vitiello B, Towbin K: Stimulant treatment of ADHD and risk of sudden death in children. *Am J Psychiatry* 2009;166(9):955-957.
21. Vitiello B: The importance of the discourse on the method. *Child Adolesc Psychiatry Mental Health* 2010; 4:2.
22. Kohlstadt I, Vitiello B: Adverse Effects of Antipsychotic Medications. *Am Family Physician* 2010; 81:
23. Goldbeck L, Vitiello B. Reporting Clinical Trials of Psychosocial Interventions in Child and Adolescent Psychiatry and Mental Health. *Child Adolesc Psychiatry Ment Health*. 2011 Feb 28;5(1):4.
24. Vitiello B. How effective are the current treatments for children diagnosed with manic/mixed bipolar disorder? *CNS Drugs*. 2013; 27(5):331-333.
25. Vitiello B, Grabb M. The development of targeted neurobiological therapies in child and adolescent psychiatry. *J Am Acad Child Adolesc Psychiatry* 2013; 52:775-779.

Letters

1. Vitiello B, Behar D, Wolfson S, Delaney MA: Panic disorder in prepubertal children. *Am J Psychiatry* 1987;144:524-525.
2. Vitiello B, Behar D, Ryan P, Malone R, Delaney MA: Saliva lithium monitoring. *J Am Acad Child Adolesc Psychiatry* 1987; 26:812.
3. Malone R, Behar D, Vitiello B, Delaney MA: Reliability and validity of the DICA. *J Am Acad Child Adolesc Psychiatry* 1987; 27:261.
4. Vitiello B, Behar D, Wolfson S, McLeer SV: On children with panic disorder. *Am J Psychiatry* 1990; 147:377.
5. Vitiello B, Yeung J, Friedman E: Plasma and saliva nortriptyline levels in a case of black tongue. *Clin Pharmacy* 1990; 9:421-422.
6. Grothe DR, Sunderland T, Vitiello B, Martinez R, Harris P: Supersensitivity to subcutaneous lidocaine. *Clin Pharmacy* 1990; 9:338.
7. Vitiello B, de Leon J: On dysmorphophobia misdiagnosed as obsessive-compulsive disorder. *Psychosomatics* 1990; 31:469.

8. Simpson GM, Singh H, Hunt J, Vitiello B: Supersensitivity psychosis. *J Clin Psychiatry* 1991; 52:90.
9. Molchan SE, Vitiello B, Minichiello M, Sunderland T: Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer's disease. *Arch Gen Psychiatry* 1991; 48:1113-1114.
10. Scahill L, Vitiello B: Risperidone in children with autism and serious behavioral problems. *N Engl J Med* 2002;347:1891.
11. Preston RJ, Kollins SH, Swanson JM, Greenhill LL, Wigal T, Elliott GR, Vitiello B: Comments on 'Cytogenetics effects in children treated with methylphenidate' by El-Zein et al. *Cancer Letters* 2005; 230:292-4.
12. Scahill L, Aman MG, McCracken JT, McDougle CJ, Vitiello B: Beware of over-interpreting negative trials. *J Autism Developmental Disorders* 2008;July 2 (Epub ahead of print).
13. Vitiello B: Truly independent research? The Treatment for Adolescents with Depression Study (TADS). *BMJ* 2008;337:a2070.
14. Aman M, Arnold LE, Lecavalier L, Hollway JA, Mulick JA, McDougle CJ, Swiezy NB, Stigler KA, Handen BL, Johnson C, Vitiello B, Bearss K, Dziura J, Scahill L: Risperidone and parent training in pervasive developmental disorders (reply to letter). *J Am Acad Child Adolesc Psychiatry* 2010; 49:407-408.
15. Vitiello B, Riddle MA, Gayane Yenokyan, Axelson DA, Birmaher B, Ryan ND, Wagner KD, Joshi P, Robb A, Walkup JT, Luby J, Rebecca Tillman, Emslie G. Letter to the editor: Reply to Another look at the Treatment of Early-Age Mania (TEAM) Trial. *J Am Acad Child Adolesc Psychiatry*. 2013 Feb;52(2):206-7. doi: 10.1016/j.jaac.2012.11.003.

Book Chapters

1. Sunderland T, Molchan S, Martinez R, Vitiello B, Martin P: Drug challenge strategies in Alzheimer disease: a focus on the scopolamine model. In Becker R and Giacobini E (editors): *Alzheimer Disease: Current Research in Early Diagnosis*. Taylor & Francis, New York, NY, 1990, pp.173-191.
2. Sunderland T, Molchan S, Vitiello B, Martinez R, Martin A: Functional cholinergic receptor sensitivity: the role of drug probes. In Becker R and Giacobini E (editors): *Cholinergic Basis for Alzheimer Therapy*. Birkhauser: Boston, 1991.
3. Vitiello B, Sunderland T: Neuropharmacology of benzodiazepines in aging. In Racagni et al. (editors): *Biological Psychiatry – Volume 1*, pp. 755-756, Amsterdam: Elsevier Science Publishers B.V., 1991.
4. Vitiello B, Molchan SE, Martinez RA, Putnam KT, Lawlor BA, Mellow AM, Weingartner H, Murphy DL, Sunderland T: MAO-B inhibitor treatment in Alzheimer's disease: cognitive effects, behavioral changes and effects on CSF monoamine metabolites. In Nicolini M, Zatta PF, and Corain B (editors): *Alzheimer's Disease and*

Related Disorders. Advances in the Biosciences. Pergamon Press: Oxford, 1993; 87:457-460.

5. Vitiello B, Jensen PS: Disruptive behavior disorders. In Kaplan HI & Sadock BJ (editors): *Comprehensive Textbook of Psychiatry*. Sixth edition, Vol. 2, Chapter 39. Williams & Wilkins: Baltimore, MD 1995.
6. Leonard H, Jensen PS, Vitiello B, Ryan N, March J, Riddle M, Biederman J: Ethical issues in psychopharmacological treatment studies in children and adolescents. In Hoagwood K, Jensen PS & Fisher CB (editors): *Ethical Issues in Research in Children and Adolescents*, Hillsdale, NJ: Lawrence Erlbaum Assoc., 1995.
7. Vitiello B, Stoff DM: Neurotransmitters and psychopharmacology of impulsive aggression in children. In: Hollander E & Stein DJ (editors): *Impulsivity and Aggression*. Chichester, UK: Wiley & Sons, 1995, pp. 229-242.
8. Stoff DM, Vitiello B: Role of serotonin in aggression of children and adolescents: Biochemical and pharmacological studies. In Stoff DM & Cairns RB (editors): *Aggression and Violence: Genetic, Neurobiological, and Biosocial Perspectives*. Mahwah, NJ: Lawrence Erlbaum Assoc., 1996, pp. 101-123.
9. Vitiello B: Research trends in depressive disorders of youth. In: Maj M and Sartorius N (eds): *Depressive Disorders*. World Psychiatric Association Series *Evidence and Experience in Psychiatry* 1999;1:295-296.
10. Vitiello B, Burke LB: Generic methylphenidate versus brand Ritalin: Which should be used? In Greenhill LL & Osman BB (editors): *Ritalin: Theory and Practice*, 2nd edition. Mary Ann Liebert Publishers: Larchmont, NY, 1999, pp. 363-367.
11. Vitiello B: Ethical Issues in pediatric psychopharmacology research. In: Rosenberg D, Gershon S, Davanzo P (editors), *Pharmacotherapy for Child and Adolescent Psychiatric Disorders*. Marcel Dekker: New York, NY, 2002, pp. 7-22.
12. Pine D, Alegria M, Cook EH, Costello EJ, Dahl RE, Koretz D, Merikangas KR, Reiss AL, Vitiello B: Advances on developmental science and DSM-V. In: Kupfer DJ, First MB, and Regier DA (editors), *A Research Agenda for DSM-V*. American Psychiatric Association: Washington, DC, 2002.
13. Vitiello B: Clinical trials methodology and design issues. In: Martin A, Scahill L, Charney D, Leckman JF (editors), *Child and Adolescent Psychopharmacology*. Oxford University Press: New York, NY, 2003.

14. Vitiello B: Children mental health issues. In: Post, SG (editor), *Encyclopedia of Bioethics*, 3rd edition. New York: Macmillan, 2004.
15. Brown RT, Antonuccio DO, DuPaul GJ, Fristad MA, King CA, Leslie LK, McCormick GS, Pelham WE, Vitiello B: *Childhood Mental Health Disorders: Evidence Base and Contextual Factors for Psychosocial, Psychopharmacological, and Combined Interventions*. American Psychological Association: Washington, DC, 2007.
16. Vitiello B: Developmental aspects of pediatric psychopharmacology. In: Findling RL (editor): *Clinical Manual of Child and Adolescent Psychopharmacology*. American Psychiatric Press: Washington, DC, 2007.
17. Vitiello B: Ethical and regulatory aspects in the treatment of children and adolescents with bipolar disorders. In: Geller B & DelBello MP (editors): *Treatment of Bipolar Disorders in Children and Adolescents*. Guilford Press: New York, NY, 2008.
18. Vitiello B, Abikoff HB, Chuang SZ, Kollins SH, McCracken JT, Riddle MA, Swanson JM, Wigal T, McGough JJ, Ghuman JK, Wigal SB, Skrobala AM, Davies M, Posner K, Cunningham C, Greenhill LL: Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). In: Luby LJ & Riddle MA (editors): *Advances in Preschool Psychopharmacol*. Mary Ann Liebert, Inc.: New Rochelle, NY, 2008. [Previously published in the *J Child Adolesc Psychopharmacology* in 2007]
19. Vitiello B: The need for specifically targeted and precise treatments aiming for remission. In: Herrman H, Maj M, Sartorius N (eds): *Depressive Disorders*. Third edition. Wiley-Blackwell: Chichester, West Sussex, UK, 2009.
20. Vitiello B, Scahill L: Clinical trials methodology and designs. In: Martin A, Scahill L, and Kratochvil CJ (editors), *Child and Adolescent Psychopharmacology*, 2nd edition. Oxford University Press: New York, NY, 2011.
21. Vitiello B: Principles in using psychotropic medication in children and adolescents. In: Rey JM (editor). *IACAPAP e-Textbook of Child and Adolescent Mental Health*. Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions, 2012.

Books, Textbooks

Vitiello B, Masi G, Marazziti D: *Handbook of Child and Adolescent Psychopharmacology*. London, UK: Francis & Taylor, 2006.

Other publications

1. Stoff D, Vitiello B: L'anatomia dell'Io: genesi delle malattie mentali. *Corriere Medico* 1985;99:7.
2. Vitiello B, Behar D: Children at risk for schizophrenia. *J Hosp Comm Psychiatry* 1986;37:293.
3. Sunderland T, Molchan SE, Martinez RA, Vitiello B: Treatment approaches to atypical depression in the elderly. *Psychiatric Annals* 1990; 20: 474-478.
4. Haigler HJ, Cott JM, Rudorfer MV, Schoenfeld RE, Potter WZ, Vitiello B, Everist HD: Psychotherapeutic Medications Development Program (PMDP). *Psychopharmacol Bull* 1993;29:241-247.
5. Jensen PS, Vitiello B, Leonard H, Laughren TP: Design and methodology issues for clinical treatment trials in children and adolescents. Child and Adolescent Psychopharmacology: expanding the research base. *Psychopharmacol Bull* 1994;30:3-8.
6. Vitiello B, Jensen PS: Developmental perspectives in pediatric psychopharmacology. *Psychopharmacol Bull* 1995;31:75-81.
7. Vitiello B, Jensen PS: Psychopharmacology in children and adolescents: Current problems, future prospects. Summary notes of the 1995 NIMH-FDA conference. *J Child Adolesc Psychopharmacol* 1995;5:5-7.
8. Vitiello B, Stover E: Psychopharmacology in HIV-positive patients: research perspectives. *Psychopharmacol Bull* 1996;32:293-297.
9. Vitiello B, Vitkovic L: The links between infections and psychiatric diseases. *Medscape* (www.medscape.com) 1997;2(4).
10. Vitiello B: Long-term effects of stimulant medications in AD/HD children. *Attention!* 2000;7:9-10.
11. Vitiello B: Treatment of adolescents with depression: research update. *The Economics of Neuroscience* 2000;2:46-48.
12. Vitiello B: Assessing efficacy and safety in pediatric psychopharmacology. *Giornale di Neuropsichiatria dell'Eta' Evolutiva* 2001;21:53-63.

13. Vitiello B, Hoagwood K: On the Need for Further Research on ADHD. *The Economics of Neuroscience* 2001; 3:30-31.
14. Vitiello B: Commentary to the report *Valproic Acid and Risperidone*. *J Am Acad Child Adolesc Psychiatry* 2001;40:867.
15. Bhatara VS, Feil M, Hoagwood K, Vitiello B, Zima B: Trends in combined pharmacotherapy with stimulants for children. *Psychiatric Services* 2002;53:244.
16. Wagner A, Vitiello B: Adolescent depression. *Current Psychiatry* 2002;1:41-50.
17. Swanson JM, Arnold LE, Vitiello B, Abikoff HB, Wells KC, Pelham WE, March JS, Hinshaw SP, Hoza B, Epstein JN, Elliott GR, Greenhill LL, Hechtman L, Jensen PS, Kraemer HC, Kotkin R, Molina B, Newcorn JH, Owens EB, Severe J, Hoagwood K, Simpson S, Wigal T, Hanley T; MTA Group: Multimodal Treatment of Children with Attention Deficit Hyperactivity Disorder. Response to commentary on the multimodal treatment study of ADHD (MTA): mining the meaning of the MTA. *J Abnorm Child Psychol* 2002;30:327-332.
18. Frank E, Rush AJ, Blehar M, Essock S, Hargreaves W, Hogan M, Jarrett R, Johnson RL, Katon WJ, Lavori P, McNulty JP, Niederhe G, Ryan N, Stuart G, Thomas SB, Tollefson GD, Vitiello B: Skating where the puck is going to be: a plan for clinical trials and translational research in mood disorders. *Biol Psychiatry* 2002;52:631-654.
19. Lebowitz BD, Vitiello B, Norquist GS: Approaches to multisite clinical trials: the National Institute of Mental Health perspective. *Schizophrenia Bull* 2003;29:7-13.
20. Vitiello B, Wagner A: Government initiatives in autism clinical trials. *CNS Spectrums* 2004; 9:66-70.
21. Vitiello B: Prevention and treatment of the psychological consequences of trauma in children and adolescents. *Epidemiol Psychiat Soc* 2004;13:10-13.
22. Posey DJ, McDougle CJ, Aman MG, Arnold LE, Scahill L, McCracken JT, Tierney E, Vitiello B, Chuang S, RUPP Autism Network. A Randomized, Double-blind, Placebo-controlled, Crossover Trial of Methylphenidate in Children with Hyperactivity Associated with Pervasive Developmental Disorders. *Neuropsychopharmacology* 2004; 29 (suppl.1): S142.
23. Vitiello B: The Treatment of Adolescents with Depression Study (TADS): Efficacy results. *Neuropsychopharmacology* 2004; 29 (suppl.1): S20.

24. Pathak S, Kratochvil CJ, Rogers GM, Silva S, Vitiello B, Weller EB, March JS: Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the Treatment for Adolescents with Depression Study. *Curr Psychiatry Rep* 2005;7:429-434.
25. Vitiello B: Commentary to Reyes et al.: Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders. *Evidence Based Mental Health* 2006;9:105.
26. Vitiello B: Combined fluoxetine with cognitive-behavioral therapy vs. monotherapy in the treatment of adolescents with major depressive disorder. *Directions in Psychiatry* 2007;27:73-82.
27. Arnold LE, Swanson JM, Hechtman L, Vitiello B, Molina BSG, Jensen P, Hinshaw SP, Wigal T: Understanding the 36-month MTA follow-up findings in context. *Attention* April 2008.
28. Vitiello B: Review of the book “Comfortably Numb: How Psychiatry Is Medicating a Nation” by C. Barber, for *Psychiatric Times* 2009; 26:13.
29. Wigal SB, Wigal TL, Swanson JM, Greenhill L, Riddle M, Vitiello B, Steinhoff KW: Preschool ADHD Treatment Study: an overview of the initial findings. *Advances in ADHD* 2008;2:79-84.
30. Vitiello B: ADHD psychopharmacology across the lifespan. *The Year in ADHD* 2008. Philadelphia, PA: Current Medicine Group, 2009.
31. Kohlstadt I, Correll C, Rappley M, Robb A, Vitiello B: Atypical antipsychotics in children and adolescents: balancing safety and efficacy. *Audio-Digest Pediatrics* 2009;55(16) (CD).
- 32.

Teaching

- 1985-87 Division of Child Psychiatry, Dept. of Psychiatry, Medical College of Pennsylvania, Philadelphia: Course of Pediatric Psychopharmacology (total of 8 lectures:
 - Principles of Pharmacokinetics
 - Pharmacological treatment of hyperactivity

- Use of antidepressants in children
 - Pharmacological treatment of aggression in children
 - Pharmacotherapy in the mentally retarded
 - Tic disorders: diagnosis and treatment
 - Use of lithium carbonate in children
 - Behavioral effects of caffeine
- 1992-96 Child Psychiatry Residency Program, Dept. of Psychiatry, Georgetown University School of Medicine, Washington, DC:
- Biological Psychiatry Research in Children and Adolescents
- April 2000 The Children's Hospital of Philadelphia, Philadelphia, PA: *Child and Adolescent Psychopharmacology in the New Millennium*:
- Drug-drug Interactions and the Risk of Polypharmacy in the Treatment of Children and Adolescents.
- June 2000 New York University, New York, NY: *Anxiety Disorders in Youth: 2000 and Beyond*:
- Bridging the gap from research to clinical practice.
- July 2000 University of Pisa, Italy:
- Methods for Assessing Treatment Effects in Child and Adolescent Psychiatry.
- Feb. 2003 University of Rome, Italy:
- Psychopharmacological Treatment of Depression in Children and Adolescents
- July 2003 University of Rome, Italy:
- Research Methodology to Assess the Effects of Treatment Interventions in Child Psychiatry (a 3-day course: July 7-9, 2003).
- Nov. 2004 Visiting Professor at the University of Ulm, Ulm (Germany):
- Research methods in child treatment research
 - Testing treatment interventions for children and adolescents with ADHD
 - Effectiveness and safety of treatment interventions in depressed adolescents
 - Testing the effects of preventive interventions for children
 - Developing interventions for youths at high risk for suicidal behavior
 - Future developments of child treatment research
- Dec. 22, 2004 University of Catania, Italy:
- Lecture: New research data on the effects of stimulant medications for the treatment of children with ADHD.
- June 2, 2005 Robert Wood Johnson University of Medicine and Dentistry of New Jersey, Piscataway, NJ:
- Lecture: Searching for Predictors and Moderators of Treatment Response in Adolescent Depression

- March 6-8, 2006
Dept. of Child and Adolescent Psychiatry, Albert Einstein University of Ulm, Ulm (Germany): lectures and seminars on:
- Adolescent depression and its treatment
 - Suicidal behavior in youths and its management
 - Aggressive behavior in childhood and its treatment
- September 2006
Division of Child and Adolescent Psychiatry, Johns Hopkins University, Baltimore, MD: research seminar for developing novel research projects in child mental health.
- June 2007
University of Rhode Island: Annual Summer Institute in Pharmacoepidemiology: a series of three lectures on pediatric psychopharmacology.
- September 2007
Division of Child and Adolescent Psychiatry, Johns Hopkins University, Baltimore, MD: research seminars on treatment research in child mental health.
- February 25, 2009
Division of Child and Adolescent Psychiatry, Johns Hopkins University, Baltimore, MD: seminar on new developments in child and adolescent research.
- June 2009
Review of atypical antipsychotics in children and adolescents: recording of discussion with other experts in pediatric pharmacology for CME of pediatricians (Audio-Digest Pediatrics volume 55, issue 16, 2009).
- January 2010
Division of Child and Adolescent Psychiatry, Johns Hopkins University, Baltimore, MD: seminar on new approaches to treatment research
- July 2010
Visiting Professor to the Division of Pediatric Neuropsychiatry at the University of Catania Medical School, Catania, Italy, where I gave lectures on developmental psychopharmacology, epidemiology of autism, treatment of psychosis in childhood, bipolar disorder in children and adolescents, treatment of youths with depression, and management of suicide risk in adolescence.
- October 2010
Case Western Reserve University/Division of Child and Adolescent Psychiatry: Motto Endowed Lecture on Oct. 15, 2010: *Treatment of Depression in Youth: Current Evidence and Research Perspectives.*
- January 2011
Children's National Hospital, Washington, DC: Seminar on *Management of Adolescents at High Risk for Suicide.*

- February 2011 Johns Hopkins University- Division of Child and Adolescent Psychiatry: lecture on *Variation in Child Psychiatry Practices: Influence of Cultural and Economic Factors*.
- Sept. 30, 2011 Navy Medical Center, Bethesda, MD, Grand rounds: *Long-Term Treatment Effects in Child and Adolescent Psychiatry*.
- March 8, 2012 Georgetown University Dept. of Psychiatry, Grand rounds: *Adolescent Psychiatry: Approaches to Treatment*.
- July 21, 2012 Hopital Salpetriere, Paris, France, *Effectiveness and safety of antidepressant medications in children and adolescents*.
- June 21-22, 2013 Washington School of Psychiatry, Washington, DC, *Attention Deficit/Hyperactivity Disorder: From Clinical Phenomenology to Neurobiology and Back*.
- Sept. 13, 2013 Dept. of Child and Adolescent Psychiatry, George Washington University, Washington, DC, *Antipsychotic Use in Children and Increased Risk of Diabetes*.
- Nov. 8, 2013 Dept. of Child and Adolescent Neuro-Psychiatry, University of Turin, Italy, *Towards a better integration of pharmacological and psychosocial interventions in child psychiatry*.
- Nov. 12, 2013 Dept. of Child and Adolescent Neuro-Psychiatry, University of Pavia, Italy, *In search of more specific and effective treatments in child psychiatry*.
- Nov. 15, 2013 Dept. of Child Neuro-Psychiatry, Catholic University Gemelli, Rome, Italy, *Toward more focused treatments in child and adolescent psychiatry*.
- March 13-14 German Society of Child Psychiatry, Berlin, Germany, *Workshop on research project preparation and reporting*.

CLINICAL ACTIVITIES

Certification

Medical Licenses:

- Maryland, 1989, #D39092 (active)
- District of Columbia, 1991, #19117 (active)
- Virginia, 1989, #0101044251 (inactive)
- West Virginia, 1990, #15993 (inactive)
- Pennsylvania, 1986, #md-040127-L (inactive)
- Italy, 1978 (inactive)

Diplomate in Pediatrics, Italy, 1981

E.C.F.M.G. Certification (V.Q.E.), 1982, #3544863

F.L.E.X. Certification, 1985

Board Certification in Psychiatry (American Board of Neurology and Psychiatry), 1992, #036497

Hospital privileges: Suburban Hospital, Bethesda, Maryland (2009-current)

ORGANIZATIONAL ACTIVITIES

Editorial Activities

Editorial board appointments (current): J Child Adolesc Psychopharmacol (since 1999), Child and Adolescent Psychiatry and Mental Health (since 2007), Poiesis and Praxis (since 2008), Clinical Therapeutics (since 2009), CNS Drugs (since 2006).

Served as a peer reviewer for the following journals in the last three years (year of most recent review in parentheses):

Acta Psychiatrica Scand (2008), Am J Managed Care (2005), Am J Med Genetics (2008), Ambulatory Pediatrics (2006), Am J Psychiatry (2012), Arch Pediatrics Adolesc Med (2011), Biol Psychiatry (2010), Biomedical Informatics Insights (2009), BioSocieties (2007), Bipolar Dis (2008), BMC Psychiatry (2013), Br J Pharmacy Pharmacology (2000), Can J Med (2005), Child Adolesc Mental Health (2011), Child Adolesc Psychiatry Mental Health (2014), Clinical Investigation (2010), CNS Drugs (2014), CNS Neuroscience & Therapeutics (2010), Current Opinion in Psychiatry (2007), Drug Safety (2008), Early Intervention in Psychiatry (2013), Epidemiology Psychiatric Services (2012), Eur Child Adolesc Psychiatry (2013), Eur J Pediatrics (2007), Eur Neuropsychopharmacol (2007), Eur Psychiatry (2011), Functional Neurology (2013), HIV Medicine (2006), Human Psychopharmacol Clin Experim (2011), J ADHD Related Disorders (2010), J Adolesc Health (2005), J Am Acad Child Adolesc Psychiatry (2012), JAMA (2013), JAMA-Psychiatry (2013), J Child Adolesc Psychopharmacol (2012), J Child Psychol Psychiatry (2012), J Clin Investigation (2006), J Clin Psychopharmacol (2014), J Clin Psychiatry (2008), J Mental Retardation (2000), J Pediatrics (2009), J Ped Psychol (2009), Lancet (2012), Life Sciences (2007), Nature Medicine (2011), Neurochemistry Intern (2006), Neuropsychiatry (2013), Neuropsychopharmacol, N Engl J Med (2009), Pediatrics (2013), Pediatric Drugs (2013), Progr Neuropharmacol Biol Psychiatry (2009), Psychiatry Research (2009), Psychopharmacol Bull (1998), Psychopharmacology (2012), Research in Autism Spectrum Disorders (2013), Social Sci Med (2007), Social Psychiatry and Psychiatric Epidemiology (2012).

Advisory Activities

Voting consultant to the Food and Drug Administration Pediatric Advisory Committee, June 30, 2005 (Safety of medications for ADHD) and March 22, 2006 (Safety of medications for ADHD).

Consultant to the Agency of Healthcare Research and Quality (AHRQ) Effective Health Care Program for the treatment of attention deficit/hyperactivity disorder (2006-2007) and bipolar disorder in children (2007).

Served as ad hoc peer reviewer for research grant applications to the U.K. Medical Research Council (2008) and AHRQ (2008).

Voting consultant to the Food and Drug Administration Psychopharmacology Advisory Committee, June 9-10, 2009.

Reviewer of research applications for the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn, Germany, 2009.

Voting consultant to the Food and Drug Administration Pediatric Advisory Committee, December 8, 2009.

Member of the Scientific Council of the National Alliance of Mental Illness (2010-2011).

Member of the Committee on Research of the American Academy of Child and Adolescent Psychiatry (2010-2012).

Scientific reviewer for the Italian Ministry of Health (2010-2011).

Scientific reviewer for the German Federal Ministry of Education and Research (BMBF), 2011.

Member of the AHRQ DEcIDE Stakeholder Committee, 2011.

Scientific advisor to the European ADHD Drug Use Chronic Effects Study (ADDUCE), 2011.

Scientific advisor to the Italian National Health Institute (Istituto Superiore di Sanita'), Rome, Italy, on the practice guidelines for the treatment of autism spectrum disorders in children and adolescents (2011).

Scientific advisor to the U.S. Agency for Healthcare Research and Quality (AHRQ) for the use of antipsychotic medications in children and adolescents (2011).

Scientific advisor to the U.S. Agency for Healthcare Research and Quality (AHRQ) for research needs in the treatment of ADHD in children and adolescents (2011).

Scientific advisor to the U.S. Agency for Children and Families (ACF) for the use of psychiatric medications in foster care children (2011).

Scientific reviewer of the ADHD Clinical Practice Points of the Australian National Health & Medical Research Council (2011).

Member of the Research Committee of the American Academy of Child and Adolescent Psychiatry (2011-current).

Scientific reviewer for the Italian Ministry of Health (2012).

Scientific ad hoc reviewer for NIMH intramural research protocols (2012).

Scientific reviewer for the Netherlands Organisation for Health Research and Development (ZonMw) (2014).

Professional Societies

Society of Biological Psychiatry (since 1996)

International Society for Research in Child and Adolescent Psychopathology (since 1990)

American Academy of Child and Adolescent Psychiatry (since 2008)

European College of Neuropsychopharmacology (since 2009)

International Neuroethics Society (since 2009)

Conference Organizer

34th Meeting of New Clinical Drug Evaluation Unit (NCDEU)-NIMH. Organization of the workshop *Developing Clinical Trials in Children and Adolescents* and of the panel *New Developments in Psychosocial, Pharmacological, and Combined Treatments of Conduct Disorders in Aggressive Children*. Marco Island, FL, May 1994.

National Institute of Mental Health (NIMH): Organization of the conference *Psychopharmacology in Children and Adolescents: Current Problems, Future Perspectives*, J Washington, DC, January 1995.

35th Meeting of NCDEU. Organization of the workshop *Methodological Issues in Treatment Research with Children and Adolescents* and of the panel *Selective Serotonin Reuptake Inhibitors in Children and Adolescents*. Orlando, FL, May 1995.

36th Meeting of NCDEU, May 1996: Organization of the workshop *Role of Manuals and Algorithms in Treatment Research with Children and Adolescents*. Boca Raton, FL, May 1996.

37th Meeting of NCDEU, May 1997: Organization of the workshop *Assessment of Functional Impairment in Treatment Research with Children and Adolescents*. Boca Raton, FL, May 1997.

38th Meeting of NCDEU: Organizer and chair of the workshop *Models for Translating Efficacy Trials* and of the panel *Mood Stabilizers in Children and Adolescents: Efficacy and Safety*. Boca Raton, FL, June 1998

NIMH: Organizer and co-chair of the workshop *Research on Eating Disorders: Current Status, Future Prospects*, Bethesda, MD, December 1998.

- NIMH: Organizer and chair of the workshop *Early Recognition and Treatment of Schizophrenia and Bipolar Disorder In Children and Adolescents*. Bethesda, MD, May 1999.
- 39th Meeting of NCDEU: Organizer and chair of the workshop *Clinical Trials in Children and Adolescents: The Interface between Researchers, Industry, NIMH, and FDA* and of the panel *Adverse Events and Safety of Psychotropic Drugs: Recognition and Treatment: II. Children and Adolescents*. Boca Raton, FL, June 1999.
- 9th Scientific Meeting of the International Society for Research in Child and Adolescent Psychopathology: Organizer and chair of panel: *Testing the Effects of Pharmacological and Psychological Treatments for Children and Adolescents: Outcome Measures and Research Designs*. Barcelona, Spain, June 1999.
- NIMH: Organizer of the workshop *Long-Term Effects of Stimulant Medications on the Brain: Possible Relevance to the Treatment of ADHD*, Bethesda, MD, December 1999.
- 40th Meeting of NCDEU: Organizer and chair of the workshop *Methodological Challenges in Pediatric Clinical Trials* and of the panel *NIMH Multisite Trials in Children and Adolescents*, Boca Raton, FL, May 30-June 2, 2000.
- NIMH: Organizer and chair of the workshop *Psychopharmacology for Young Children: Clinical Needs and Research Opportunities*. Bethesda, MD, October 2000.
- 41st Meeting of NCDEU: Organizer of the workshop *Treatment Research in Children and Adolescents: from Design to Implementation of Clinical Trial* and of the panel *Developmental Pharmacokinetics and Pharmacodynamics of Psychotropics*. Phoenix, AR, May 28-June 1, 2001.
- 42nd Meeting of NCDEU: Organizer and chair of the workshop *Developing through Research Evidence-Based Treatments in Child and Adolescent Mental Health* and of the panel *Assessing Safety in Pediatric Psychopharmacology*, Boca Raton, FL, June 10-13, 2002
- 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry: Organizer of the symposium *The RUPP Network: Recent Findings and New Directions*. San Francisco, CA, Oct. 22-27, 2002.
- 43rd Meeting of NCDEU: Organizer of the workshop *Beyond Short-Term Treatment Effects: Can We Change the Course of Illness Through Treatment?* Boca Raton, FL, May 27-30, 2003.
- 44th Meeting of NCDEU: Organizer and chair of the workshop *NIMH-Funded Multisite Trials in Children and Adolescents with Depression and Anxiety Disorders* and of the panel *Advances in the Treatment of ADHD from Preschool to Adulthood*. Phoenix, AZ, June 1-4, 2004.

- 51th Annual Meeting of the American Academy of Child and Adolescent Psychiatry: Organizer and chair of the symposium *The Treatment for Adolescents with Depression Study (TADS)*. Washington, DC, Oct. 19-24, 2004.
- 46th Meeting of NCDEU: Organizer and chair of the panel *Medication Management of Mania in Children and Adolescents*. Boca Raton, FL, June 14, 2006.\
- 46th Meeting of NCDEU: Organizer and chair of the workshop *Research Advances in the Treatment of Major Depression in Children and Adolescents*. Boca Raton, FL, June 14, 2006.
- 47th Meeting of NCDEU: Organizer and chair of the panel *Design and Methodological Challenges in Child and Adolescent Clinical Trials*. Boca Raton, FL, June 11, 2007.
- 13th Scientific Meeting of the International Society for Research in Child and Adolescent Psychopathology: Organizer and chair of the symposium *Treatment of Depression in Adolescence: What is the Evidence for Effectiveness?* London, UK, June 20-23, 2007.
- 161th Annual Meeting of the American Psychiatric Association: Organized and chaired the symposium *Safety Issues in Child and Adolescent Psychopharmacology*. Washington, DC, May 5, 2008.
- 49th Meeting of NCDEU: Organizer and chair of the panel *Mood Stabilizers in Childhood Bipolar Disorders*. Hollywood, FL, June 29-July 2, 2009.
- 49th Meeting of NCDEU: Organizer and chair of the workshop *Developing a Research Framework for Personalizing Mental Health Care*. Hollywood, FL, June 29-July 2, 2009.

RECOGNITION

Awards (selection)

- | | |
|-----------|---|
| June 1996 | National Institutes of Health Director's Award, "In recognition of outstanding dedication and work in ensuring the safe and thorough evaluation of an experimental AIDS therapeutic agent". |
| June 2000 | National Institutes of Health Director's Award, "In recognition of your outstanding commitment in organizing and launching the new clinical trials program of NIMH". |
| May 2001 | Food and Drug Administration. Group Recognition Award, as a member of the Development of Psychotropic Drugs in Young Children Working Group, "For outstanding performance implementing a White House initiative to promote and ensure that children with mental health conditions are appropriately diagnosed, treated, and monitored". |

- May 2006 National Institute of Mental Health Director's Award, "for commitment to understanding the safety and efficacy of therapeutic interventions for children and adolescents".
- June 2006 U.S. DHHS Secretary's Award for Distinguished Service, for providing increased capacity for mental health and substance abuse treatment services following hurricanes Katrina, Rita and Wilma."

OTHER PROFESSIONAL ACCOMPLISHMENTS

Selection of presentations at scientific and professional meetings

1. Ferrando A, Romano L, Pesce F, Vitiello B: Left ventricular function in the cor pulmonale in children. International Meeting on Bidimensional Echocardiography, Milan, Oct. 29-30, 1980.
2. Itil TM, Songar A, Bozak M, Vitiello B, Lucadamo F: Tolerance and Quantitative EEG in man with DL 181, an anxiolytic with a new pharmacological profile. 13th Congress, Collegium Internationale Neuro-Psychopharmacologicum, Jerusalem, June 20-25, 1982. Abstract book: p. 338.
3. Vitiello B, Itil TM, et al.: Pharmacokinetics of premarizepam in volunteers and a pilot tolerability study in anxious patients. 2nd World Conference on Clinical Pharmacology & Therapeutics, Washington, DC, July 31-Aug. 5, 1983. Abstract book: p. 537.
4. Vitiello B, Behar D, et al.: Diagnosis and neuropsychological findings in the offspring of obsessive-compulsive disorder patients. 4th World Congress of the Society of Biological Psychiatry, Philadelphia, Sept. 8-13, 1985. Abstract book: p. 337.
5. Behar D, Stoff D, Pollock L, Vitiello B, Lee D, Bridger WH: Decreased imipramine binding in child aggression. 139th Meeting of the American Psychiatric Association, Washington, DC, May 10-16, 1986. Abstract book: p. 40.
6. Ricciuti A, Behar D, Vitiello B: An aggression sub-typing scale for children. 17th Meeting of the American Academy of Psychiatry and Law, Philadelphia, PA, Oct. 16-19, 1986. Abstract book: p. 57-58.
7. Vitiello B, Behar D: Panic disorder in prepubertal children. 7th National Conference on Phobias and Related Disorders, Phobia Society of America, New York, NY, Oct. 17-19, 1986.
8. Vitiello B, Behar D, et al.: Serum and saliva pharmacokinetics of lithium carbonate in children. 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, Oct. 21-25, 1987. Abstract book: p. 48.
9. Behar D, Vitiello B, et al.: Structured and unstructured interviews: reliability of diagnoses in child psychiatry. 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, Oct 21-25, 1987. Abstract book: p. 41.
10. Stoff D, Vitiello B, et al.: Impulsivity in children is related to elevated platelet MAO activity. 43th Annual Meeting of the Society of Biological Psychiatry, Montreal, May 4-8, 1988. Abstract book: p. 100.

11. Stoff D, Friedman E, Bridger WH, Pollock L, Vitiello B, Ieni J: Dissociation between platelet imipramine binding and serotonin uptake in boys. 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Seattle, WA, Oct. 26-30, 1988. Abstract book: p. 64.
12. Vitiello B, Stoff D, et al.: Impulsivity, platelet MAO, and neurological soft signs in children. 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Seattle, WA, Oct. 26-30, 1988. Abstract book: p. 65.
13. Vitiello B, Shimon H, Behar D, Stoff D, Bridger WH, Friedman E: Increased serotonin uptake in platelets of obsessive-compulsive patients. 44th Annual Convention of the Society of Biological Psychiatry, San Francisco, CA, May 4-8, 1989. Biol Psychiatry 1989; 25:7A.
14. Stoff D, Bridger WH, Friedman E, Mahoney A, Pasatiempo A, Pollock L, Vitiello B, Yeung J: Fenfluramine stimulates plasma prolactin and cortisol release in boys with disruptive behavior disorder. 44th Annual Convention of the Society of Biological Psychiatry, San Francisco, CA, May 4-8, 1989. Biol Psychiatry 1989; 25:120A.
15. Singh H, Hunt J, Vitiello B, Simpson GM: Supersensitivity psychosis: a controlled prospective double-blind withdrawal study. 44th Annual Convention of the Society of Biological Psychiatry, San Francisco, CA, May 4-8, 1989. Biol Psychiatry 1989; 25:161A.
16. Vitiello B, Behar D, Stoff D, Ricciuti A: Subtyping aggression in humans. , 142nd Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 7-12, 1989.
17. Vitiello B, Behar D, Wolfson S, McLeer SV: Panic disorder in prepubertal children. VIII World Congress of Psychiatry, Athens, Greece, Oct. 12-19, 1989. Abstract Book: p. 367.
18. Sunderland T, Molchan SE, Lalonde FM, Lowler BA, Martinez RA, Vitiello B: Combination pharmacotherapy in Alzheimer's disease: deprenyl plus physostigmine. 28th Annual Meeting of the American College of Neuro-Psychopharmacology, Maui, HI, Dec. 10-15, 1989. Abstract Book: p.79.
19. Molchan SE, Lawlor BA, Martinez RA, Rubinow DR, Vitiello B, Sunderland T: Relationship between somatostatin and 5-HIAA in Alzheimer's disease and geriatric depression. 45th Annual Convention of the Society of Biological Psychiatry, May 1990, New York, NY. Biol Psychiatry 1990; 27:122A-123A.
20. Molchan SE, Mellow AM, Hill JL, Martinez RA, Lawlor BA, Vitiello B, Martin A, Weingartner H, Sunderland T: Response to high dose thyrotropin-releasing hormone in Alzheimer's disease and age-matched controls after scopolamine infusion. 29th Annual Meeting of the American College of Neuro-Psychopharmacology, San Juan, Puerto Rico, December 1990. Abstract Book: p. 153.
21. Vitiello B, Veith RC, Molchan SE, Martinez RA, Lawlor BA, Radcliffe J, Hill JL, Sunderland T: Plasma epinephrine and norepinephrine in Alzheimer's disease and in elderly depressed without dementia. 46th Annual Convention of the Society of Biological Psychiatry, New Orleans, LA, May 1991. Biol Psychiatry 1991; 29:120A.
22. Molchan SE, Martinez RA, Vitiello B, Weingartner HJ, Sunderland T: Thyrotropin-releasing hormone effects on monoamines and cognition in humans. 46th Annual Convention of the Society of Biological Psychiatry, New Orleans, LA, May 1991. Biol Psychiatry 1991; 29:123A.

23. Vitiello B, Martin A, Molchan SE, Martinez RA, Pappas B, Sunderland T: Behavioral, physiological, and cognitive effects of blocking the cholinergic, dopaminergic, and serotonergic systems in young men. 5th World Congress of Biological Psychiatry, Florence, Italy, June 1991. *Biol Psychiatry* 1991; 29:690S.
24. Vitiello B, Martin A, Mack C, Hill J, Molchan S, Martinez RA, Sunderland T: Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. 30th Annual Meeting of the American College of Neuro-Psychopharmacology, San Juan, Puerto Rico, December 1991.
25. Molchan S, Hill JL, Minichiello M, Vitiello B, Sunderland T: Attenuation of the pressor response of TRH by scopolamine in Alzheimer patients and controls. 30th Annual Meeting of the American College of Neuro-Psychopharmacology, San Juan, Puerto Rico, December 1991.
26. Sunderland T, Molchan S, Putnam K, Martinez RA, Vitiello B, Lawlor BA, Mellow AM: CSF monoamine effects of long-term deprenyl and hydergine in Alzheimer patients. 47th Annual Convention of the Society of Biological Psychiatry, Washington, DC, May 1992. *Biol Psychiatry* 1992; 31:201A.
27. Hauser P, Zametkin A, Martinez P, Vitiello B, Weintraub B: Association of attention-deficit hyperactivity disorder with generalized resistance to thyroid hormone in 18 kindreds. 145th Annual Meeting of the American Psychiatric Association, Washington, DC, May 2-7, 1992.
28. Haigler H, Cott J, Rudofe M, Schoenfeld R, Potter W, Vitiello B, Everist H: National Institute of Mental Health Psychotherapeutic Medications Development Program. NCDEU 32nd Annual Meeting, Boca Raton, FL, May 26-29, 1992.
29. Sunderland T, Putnam K, Martinez RA, Mellow A, Lawlor BA, Vitiello B, Molchan S, Cohen RM, Weingartner H: Cognitive effects of long-term deprenyl and hydergine in Alzheimer's disease patients. C.I.N.P. 18th Congress, Nice, France, June-July 1992.
30. Vitiello B, Molchan SE, Martinez R, Putnam KT, Lawlor BA, Mellow AM, Weingartner H, Murphy DL, Sunderland T: Controlled study on the long-term use of l-deprenyl in Alzheimer patients. 3rd International Conference on Alzheimer's Disease and Related Disorders, Abano Terme, Italy, July 12-17, 1992.
31. Vitiello B: Developmental aspects in pediatric psychopharmacology. NCDEU 34th Annual Meeting, Marco Island, FL, May 31-June 3, 1994.
32. Vitiello B, Conrad T, Burkhart G, Jensen P: Survey on the use of psychotropics in children and adolescents. C.I.N.P. 19th Congress, Washington, DC, June 27-July 1, 1994.
33. Vitiello B, Stover E, Goldschmidts W, Koslow SH: HIV-induced cognitive impairment: An update on potential pharmacotherapies. C.I.N.P. 19th Congress, Washington, DC, June 27-July 1, 1994.
34. Stover E, Vitiello B, Pequegnat W: Neuropsychiatric and neuroimaging NIMH HIV-1 Research. 33th Annual Meeting of the American College of Neuro-Psychopharmacology, San Juan, Puerto Rico, December 1994.
35. Vitiello B, Pequegnat W, Stover E: New pharmacological approaches to the treatment of HIV-1 induced cognitive impairment. New Research Session, 148th Annual Meeting of the American Psychiatric Association, Miami, FL, May 20-25, 1995.
36. Vitiello B: New developments in pediatric psychopharmacology. 42nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans, LA, October 17-21, 1995.

37. Stover E, Pequegnat W, Vitiello B, Evans D: NIMH research in HIV infection. 34th Annual Meeting of the American College of Neuro-Psychopharmacology, San Juan, Puerto Rico, December 11-16, 1995.
38. Vitiello B, Goodkin K, Heaton R, Rochon J, Atkinson H, Wilkie F, Brown S, Feaster D, Goldschmidts W, Stover E, Koslow S: Factors associated with HIV-related cognitive impairment. 37th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, May 27-May 30, 1997.
39. Vitiello B: Psychopharmacology in HIV positive patients. Symposium at the 6th World Congress of Biological Psychiatry, Nice, France, June 22-27, 1997.
40. Vitiello B: Developmental aspects of child psychopharmacology. 44th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 14-19, 1997.
41. Vitiello B: Perspectives in child psychopharmacology research. 44th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, October 14-19, 1997.
42. Vitiello B: Latest research developments in the pathogenesis of neuro-AIDS. 12th World AIDS Conference, Geneva, CH, June 28-July 3, 1998.
43. Vitiello B: *Hypericum perforatum* extracts as potential antidepressants. Oral presentation. Symposium "Plants and the Central Nervous System", at the British Pharmaceutical Conference, Eastbourne, E. Sussex, UK, September 8-11, 1998.
44. Vitiello B: Research designs and coordination in pediatric psychopharmacology. II Oral presentation. Biannual International Meeting on Adolescence, Cagliari, Italy, October 9-11, 1998.
45. Vitiello B: Treatment effectiveness research in child psychiatry. Oral presentation. 45th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, CA, October 27-November 1, 1998.
46. Vitiello B: Multisite studies in child psychopharmacology: the perspective from NIMH. Oral presentation. 45th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, CA, October 27-November 1, 1998.
47. Vitiello B: Integrating science and ethics in child psychiatry. Oral presentation. 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, IL, October 19-24, 1999.
48. Vitiello B: Pediatric Psychopharmacology: NIMH-Sponsored Multi-site Studies. Oral presentation. 55th Annual Convention of the Society of Biological Psychiatry, Chicago, IL, May 11-13, 2000.
49. Vitiello B, for the RUPP Anxiety Study Group: A multi-site double-blind placebo-controlled trial of fluvoxamine for children and adolescents with anxiety disorders. Poster Session, 40th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, May 30-June 2, 2000.
50. Vitiello B: Multi-center clinical trials in child psychopharmacology. 12th Meeting of the Italian Society of Neuropsychopharmacology. Cagliari, Italy, June 7-10, 2000.
51. Vitiello B, for the RUPP Anxiety Study Group: Moderators and mediators of treatment effect in the RUPP anxiety study. Oral presentation. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 24-29, 2000.

52. Arnold LE, Severe J, Kraemer H, Vitiello B, Pelham W, for the MTA Cooperative Group: Differential enduring effects of MTA treatments at 24 months. Oral presentation. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 24-29, 2000.
53. Bhatara V, Feil M, Hoagwood K, Vitiello B, Zima BT: Concomitant psychopharmacotherapy in youth receiving antidepressants or stimulants: National trends. Poster Session. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 24-29, 2000.
54. Vitiello B: Optimal strategies for developing and implementing psychopharmacological studies in preschool children: NIMH perspective. Oral presentation. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 24-29, 2000.
55. Vitiello B: Testing extracts of Hypericum perforatum (St. John's wort) for antidepressant effects. Oral presentation. Clinical Research 2001. Arlington, VA, March 11, 2001.
56. Vitiello B: Clinical trial designs in childhood conduct disorder. Oral presentation. European College of Neuropsychopharmacology Consensus Meeting 2001, Nice, France, March 18-21, 2001.
57. Vitiello B: An NIH viewpoint: issues in psychopharmacology studies and conduct of multicenter studies. New Research Directions in Pediatric Psychopharmacology, New Brunswick, NJ, April 26-27, 2001.
58. Vitiello B: Childhood anxiety disorders: NIMH initiatives. Oral presentation. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 5-10, 2001.
59. Vitiello B: Moderators and mediators of treatment effect in the RUPP pediatric anxiety disorder trial of fluvoxamine. Oral presentation. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 5-10, 2001.
60. Vitiello B: Integrating clinical research with clinical practice: the NIMH effectiveness clinical trials. Oral presentation. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 5-10, 2001.
61. Vitiello B: Monitoring for safety in clinical trials: NIH regulations. Oral presentation: 41th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Phoenix, AR, May 28-June 1, 2001.
62. Vitiello B: Assessing the efficacy of treatment interventions in child and adolescent psychiatry. Oral presentation. Meeting of the Italian Society of Child and Adolescent Neuropsychiatry. Villasimius, Italy, June 7-10, 2001.
63. Vitiello B: Approaches to standardizing safety data collection in pediatric psychopharmacology. Oral presentation. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI, October 23-28, 2001.
64. Vitiello B: Treatment of ADHD and impact on associated dysfunctions. Oral presentation. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI, October 23-28, 2001.
65. Vitiello B: The RUPP risperidone treatment study for autism. Oral presentation. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI, October 23-28, 2001.
66. McDougle C, Aman M, McCracken JT, Scahill L, Tierney E, Vitiello B: A double-blind placebo-controlled trial of risperidone in autistic disorder. Poster at the 40th Annual

- Meeting of the American College of Neuropsychopharmacology, Waikoloa, HI, December 9-13, 2001.
67. Vitiello B: Ethical considerations in developing pharmacological treatments for children. Oral presentation. Oral presentation at the 40th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, HI, December 9-13, 2001.
 68. Vitiello B: Therapeutic use of atypical antipsychotics in children with autism. 57th Annual Convention of the Society of Biological Psychiatry, Philadelphia, PA, May 16-18, 2002.
 69. Vitiello B: Approaches to standardizing safety data collection in pediatric psychopharmacology. Oral presentation at the 57th Annual Convention of the Society of Biological Psychiatry, Philadelphia, PA, May 16-18, 2002.
 70. Vitiello B: Assessment of adverse events and preservation of 'blindness' in clinical trials. Oral presentation at the 42nd Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, June 10-13, 2002.
 71. Vitiello B: The MTA study: implications for clinical care and further research. Oral presentation at the Head Start's 6th National Research Conference, Washington, DC, June 26-29, 2002.
 72. Research Units on Pediatric Psychopharmacology Autism Network. A placebo-controlled study of risperidone in the treatment of children with autistic disorder. *Pediatric Research*. 2002, 51 (4): 458A. Poster presented at the Pediatric Academic Societies' (PAS) Annual Meeting, Baltimore, MD, May 7, 2002.
 73. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone Treatment of Autistic Disorder: Longer Term Benefits and Blinded Discontinuation After Six Months. Presented at the Society for Developmental and Behavioral Pediatrics 20th Annual Meeting, Seattle, WA, September 29, 2002.
 74. Fisher P, Greenhill LL, Vitiello B: Research assessment of medication side effects: how best to do this? Workshop at the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, October 23, 2002.
 75. Greenhill LL, Vitiello B, Fisher P, Labellarte M, March J, McMahon D, Scahill L, Zito J: NIMH's Safety Monitoring Uniform Report Form (SMURF): Feasibility Testing. Presentation at the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, October 23, 2002.
 76. Vitiello B: The clinical trial in child psychiatry: how to improve it? Oral presentation at the 19th Congress of the Italian Society of Child Neuropsychiatry, Catania, Italy, October 15, 2002.
 77. Vitiello B: Expanding the scope of the RUPP network. Oral presentation at the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, October 24, 2002.
 78. Vitiello B: A Government view point on ADHD research and practice. Oral presentation at the 130th annual meeting of the American Public Health Association, Philadelphia, PA, November 12, 2002.
 79. McDougle CJ, Aman M, McCracken JT, Scahill L, Tierney E, Vitiello B: Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after six months. Poster at the 41th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, December 8-12, 2002.

80. Vitiello B: Experience with recruitment and retention of children in mental health trials. Oral presentation at the Office of Research on Women's Health Conference *Science Meets Reality: Recruitment and Retention of Women in Clinical Studies and the Critical Role of Relevance*, Washington, DC, January 6-9, 2003.
81. Vitiello B: Prepubertal bipolar disorder. Oral presentation at the 8th Annual Congress of the Italian Society of Psychopathology, Rome, Italy, February 25-March 1, 2003 (Abstract: Italian J Psychopathology 2003;9:S14).
82. Vitiello B: Evaluation of treatment efficacy in attention deficit hyperactivity disorder. Oral presentation at the 8th Annual Congress of the Italian Society of Psychopathology, Rome, Italy, February 25-March 1, 2003 (Abstract: Italian J Psychopathology 2003;9:S99).
83. Vitiello B: The MTA study: results and consequences. International Symposium on ADHD, Congress of German Speaking Societies of Child and Adolescent Psychiatry, Vienna, Austria, April 2, 2003.
84. Vitiello B, McCracken J, Aman M, McDougle C, Scahill, Tierney E, Arnold LE, Davies M: Research knowledge among parents of children in a clinical trial. Poster presentation at the 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
85. Greenhill LL, Abikoff HB, Cunningham C, Hyman S, Kollins SH, McCracken JT, Riddle M, Skrobala A, Swanson JM, Thorp B, Vitiello B, Wigal T, Wigal SB: Recruitment into the preschool ADHD treatment study (PATS) compared with the MTA. Poster presentation at the 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
86. Vitiello B: Research methodology in evaluating the effectiveness of interventions in child psychiatry. Oral presentation at the 20th Congress of the Italian Society of Child Neuropsychiatry, Rome, Italy, November 30-December 4, 2003.
87. Vitiello B: Pediatric psychopharmacology: a perspective from the NIMH. Oral presentation. Fourth Annual Colloquium on Treatment Research in Child Psychiatry. Columbia University. March 10, 2004.
88. Vitiello B: Adolescent depression: an overview of the problem. Oral presentation. Guidelines for Adolescent Depression in Primary Care. New York Academy of Medicine, New York, NY, July 6-7, 2004.
89. Vitiello B: Children and medications: new research findings. Oral presentation at the 25th National Convention of the National Alliance for the Mentally Ill (NAMI), Washington, DC, September 11, 2004.
90. Vitiello B: Public-industry collaborative mechanisms applicable to pediatric psychopharmacology. Oral presentation at the Research Forum of the 51th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, Oct. 19-24, 2004.
91. Vitiello B: Public-industry collaborative mechanisms applicable to pediatric psychopharmacology. Oral presentation at the Research Forum of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, Oct. 19-24, 2004.
92. Vitiello B: Research progress in interventions for adolescents with depression. Oral presentation at the Research Forum of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, Oct. 19-24, 2004.

93. Vitiello B: Methods to evaluate safety in pediatric psychopharmacology. Oral presentation at the Research Forum of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, Oct. 19-24, 2004.
94. Vitiello B: Adolescents and antidepressants: facts and fiction. Oral presentation at the conference “Depression on College Campuses”, Ann Arbor, MI, March 22, 2005.
95. Vitiello B: Is There a non-therapeutic use of stimulant medications in children? Oral presentation at the conference “Hard Science, Hard Choices: Facts, Ethics, and Policies Guiding Brain Science Today”, Library of Congress, Washington, DC, May 10-11, 2005.
96. Vitiello B: Searching for moderators and mediators of treatment effect in adolescent depression. Oral presentation at the 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 21-26, 2005.
97. Vitiello B: Clinical evaluation of safety in psychopharmacology. Oral presentation at the 45th NCDEU Annual Meeting, Boca Raton, FL, June 6, 2005.
98. Vitiello B: Antidepressant treatment effects on level of functioning and global health. Oral presentation at the 12th meeting of the International Society for Research in Child and Adolescent Psychopathology. New York, NY, June 22-25, 2005.
99. Vitiello B, Abikoff H, Arnold LE, Jensen PS, Lahey B: Can Treatment studies inform on psychopathology and course of illness? Panel discussion at the 12th meeting of the International Society for Research in Child and Adolescent Psychopathology. New York, NY, June 22-25, 2005.
100. Vitiello B: Effects of antidepressant treatment on level of functioning in adolescents. Oral presentation at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, Oct. 18-23, 2005.
101. Vitiello B: Unmet needs in appropriate management of behavioral symptoms in disruptive behavior disorders. Oral presentation at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, Oct. 18-23, 2005.
102. Bhatia SK, Buehler B, Kratochvil CJ, Sitorius MA, Vitiello B: Pediatric mental health resources and antidepressant prescribing practices. Poster presentation at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, Oct. 18-23, 2005.
103. Vitiello B: Potential long-term effects of psychostimulant use in ADHD. Oral presentation at the 39th Winter Conference on Brain Research. Steamboat Springs, CO, January 21-28, 2006.
104. Vitiello B: On the efficacy of pharmacological treatment of attention deficit/hyperactivity disorder. Oral presentation at the Food and Drug Administration Pediatric Advisory Committee, Gaithersburg, MD, March 22, 2006.
105. Vitiello B: Treatments for children and adolescents with depression: How effective? How safe? Oral presentation at the symposium Demons of the Mind: 21st Century Science vs. Depression. United States Library of Congress, Washington, DC, April 19-20, 2006.
106. Vitiello B: The Treatment of Resistant Depression in Adolescent Study (TORDIA): a research update. 46th Meeting of NCDEU, Boca Raton, FL, June 13, 2006.
107. Vitiello B: Is there a place for pharmacology in the treatment of childhood anxiety disorders? Oral presentation at the 19th Congress of the European College of Neuropsychopharmacology, Paris, France, September 16-20, 2006. Eur Neuropsychopharmacol 2006;16:Supplement 4:S190.

108. Vitiello B: The Treatment for Adolescents with Depression Study (TADS). Oral presentation at the 58th Institute for Psychiatric Services, New York City, N, October 5-8, 2006.
109. Vitiello B: Effectively obtaining informed consent for research participation. Oral presentation at the Conference on Ethics of Intervention Research with Children and Adolescents with Behavioral Disorders. Cleveland Foundation, Cleveland, OH, October 16-17, 2006.
110. Vitiello B and the Preschoolers with ADHD Study Group: Long-term methylphenidate treatment of preschoolers with ADHD. Oral presentation at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, Oct. 24-30, 2006. Scientific Proceedings: pages 46-47.
111. Abikoff H, Vitiello B, Ghuman J, Posner K: Functional improvements with methylphenidate in preschoolers with ADHD. Oral presentation at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, Oct. 24-29, 2006. Scientific Proceedings: page 46.
112. Ghuman JK, Riddle M, Chuang MS, Wigal S, Vitiello B, and the Preschoolers with ADHD Study Group: Moderators of methylphenidate response in preschool children with attention-deficit/hyperactivity disorder. Oral presentation at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, Oct. 24-30, 2006. Scientific Proceedings: page 45.
113. Findling RL, Sikich L, Frazier J, McClellan J, Ritz L, Hamer R, Hooper S, Vitiello B, Lieberman J: Design of two prospective trials in early onset schizophrenia spectrum disorders. Oral presentation at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, Oct. 24-30, 2006. Scientific Proceedings: page 35.
114. McClellan J, Hlastala SA, Sikich L, Frazier J, Findling RL, Ritz L, Hamer R, Vitiello B, Lieberman J: TEOSS: baseline demographics and clinical characteristics. Oral presentation at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, Oct. 24-30, 2006. Scientific Proceedings: pages 35-35
115. Frazier JA, Giuliano AJ, Hooper S, Sikich L, Findling RL, McClellan J, Breiger D, Youngstrom E, Hamer R, Anderson R, Vitiello B, Ritz L, Lieberman JA: Neurocognition in early-onset schizophrenia: relationship to diagnosis, symptoms and communication. Oral presentation at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, Oct. 24-30, 2006. Scientific Proceedings: page 36.
116. Vitiello B: Safety issues of psychoactive drugs for children. Oral presentation at the Best Pharmaceuticals for Children Act Annual Prioritization Meeting, Bethesda, MD, Dec. 5-6, 2006.
117. Vitiello B: NIMH current research advances. Oral presentation at the 160th Annual Meeting of the American Psychiatric Association, San Diego, CA, May 19-24, 2007.
118. Vitiello B: Interpreting safety data: implications for clinical practice and research. Oral presentation at the 47th Meeting of NCDEU, Boca Raton, FL, June 11-14, 2007.
119. Vitiello B, March JS: The Treatment for Adolescents with Depression Study: Long-Term Effectiveness. Oral presentation at the 13th Scientific Meeting of the International

- Society for Research in Child and Adolescent Psychopathology, London, UK, June 20-23, 2007.
120. Vitiello B: The Treatment of Adolescents Suicide Attempters Study (TASA). Oral presentation at the 13th Scientific Meeting of the International Society for Research in Child and Adolescent Psychopathology, London, UK, June 20-23, 2007.
 121. Vitiello B: The pharmacotherapy of ADHD. Oral presentation at the 13th International Congress of the European Society of Child and Adolescent Psychiatry, Florence, Italy, August 25-28, 2007.
 122. Vitiello B: The Treatment for Adolescents with Depression Study (TADS). Oral presentation at the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Boston, MA, Oct. 23-29, 2007. Scientific Proceedings: page 263.
 123. Vitiello B: Clinical implications of the Treatment for Adolescents with Depression Study (TADS). Oral presentation at the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Boston, MA, Oct. 23-29, 2007. Scientific Proceedings: pages 98-99.
 124. Vitiello B: Adverse effects of antipsychotic treatment of early onset schizophrenia spectrum disorders. Oral presentation at the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Boston, MA, Oct. 23-29, 2007. Scientific Proceedings: pages 116-117.
 125. Vitiello B: Adverse effects of antipsychotic treatment of early onset schizophrenia spectrum disorders. Oral presentation at the 46th Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, FL, December 9-13, 2007.
 126. Vitiello B: Publicly funded and industry funded research strategies in pediatric pharmacology. Oral presentation at the Europaeische Akademie Conference on Clinical Research in Vulnerable Populations. Berlin, Germany, April 3-4, 2008.
 127. Vitiello B: Antipsychotic in children and adolescents: liability and pharmacovigilance. Oral presentation at the Treatment Expert Meeting of the European College of Neuropsychopharmacology, Barcelona, Spain, August 29, 2008.
 128. Vitiello B: ADHD and its treatment. Oral presentation at the 39th annual meeting of the Environmental Mutagen Society, Rio Grande, PR, October 18-22, 2008. Abstract S48, Environ Mol Mutagenesis 2008;49:528.
 129. Vitiello B: First, do no harm: challenges in pharmacotherapy for children. Oral presentation at the 55th annual meeting of the American Academy of child and Adolescent Psychiatry, Chicago, IL, October 28-November 2, 2008.
 130. Vitiello B: Pediatric bipolar disorder: validity and controversies. Oral presentation at the 1st Annual Meeting of the Neuroethics Society, Washington, DC, November 13-14, 2008.
 131. Vitiello B: Early onset schizophrenia and bipolar disorder. Oral presentation at the Food and Drug Administration Psychopharmacologic Drug Advisory Committee Meeting, Adelphi, MD, June 9, 2009.
 132. Vitiello B: Use of antipsychotics in children and adolescents: recent research findings. Oral presentation at the 22nd Congress of the European College of Neuropsychopharmacology, Istanbul, Turkey, September 12-16, 2009.
 133. Vitiello B, Lasky T: Child Hospitalizations for Mood Disorders in the U.S. Oral presentation at the 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI, Oct. 26-31, 2009.

134. Vitiello B: Child and adolescent depression. Oral presentation at the 9th National Congress of the Italian Society of Psychiatric Epidemiology, Matera, Italy, November 5-7, 2009.
135. Vitiello B: Quality and ethics in the psychiatric treatment during development. Oral presentation at the National Congress of the Italian Society of Child and Adolescent Neuropsychiatry, Bologna, Italy, December 17-18, 2009.
136. Vitiello B: Emerging endpoints in treatment research: different targets from different perspectives. Oral presentation at the 50th Meeting of NCDEU, Boca Raton, FL, June 14-17, 2010.
137. Vitiello B: New Developments in Pediatric Psychopharmacology Research. Oral presentation at the Research Forum - 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, Oct. 26-31, 2009.
138. Vitiello B: Mood irritability during development: phenomenology and implications for nosology and treatment. Oral presentation at the 15th Congress of the Italian Society of Psychopathology, Rome, Italy, February 15-19, 2011.
139. Vitiello B: When the brain is highly plastic: the controversial use of antipsychotics in children and adolescents. Oral presentation at the 15th Congress of the Italian Society of Psychopathology, Rome, Italy, February 15-19, 2011.
140. Vitiello B: Treatment of ADHD symptoms in the context of pervasive developmental disorders: continuity and discontinuity in the therapeutic response. Oral presentation at the 15th Congress of the Italian Society of Psychopathology, Rome, Italy, February 15-19, 2011.
141. Vitiello B: Efficacy and safety of antipsychotic treatment in early onset schizophrenia. Oral presentation at the 25th Congress of the Italian Society of Child and Adolescent Neuropsychiatry, Pisa, Italy, May 11-14, 2011.
142. Vitiello B: The Treatment of Early Age Mania (TEAM): searching for predictors and moderators of treatment effects. Oral presentation at the 51th Meeting of NCDEU, Boca Raton, FL, June 13-16, 2011.
143. Vitiello B: Effectiveness and Limitations of Psychotropics in Adolescents. Oral presentation at the 8th Congress of the International Society for Adolescent Psychiatry and Psychology, Berlin, Germany, September 14-18, 2011.
144. Vitiello B: Treatment of adolescent depression: the state-of-the-science. Oral presentation at the Joint Meeting of the American Academy of Child and Adolescent Psychiatry and the Canadian Academy of Child and Adolescent Psychiatry, Toronto, Canada, Oct. 18-23, 2011.
145. Vitiello B: The Treatment of Early Age Mania (TEAM): searching for predictors and moderators of treatment effects. Oral presentation at the Joint Meeting of the American Academy of Child and Adolescent Psychiatry and the Canadian Academy of Child and Adolescent Psychiatry, Toronto, Canada, Oct. 18-23, 2011.
146. Vitiello B: Is there a place for antidepressants in child and adolescent depression? Oral presentation at the 20th World IACAPAP Congress, Paris, France, July 21-25, 2012.
147. Vitiello B: What is the role of the National Institutes of Health and academia in drug development? Oral presentation at the 60th annual meeting of the American Academy of Child and Adolescent Psychiatry, Orlando, FL, Oct. 22-27, 2013.

